

Supplemental File: Medicines under exclusivity situation funded by the Ministry of Health: analysis of the patent situation and public procurement. Gabriela Costa Chaves, et al. Fiocruz.

Legend	Blue: excluded after analysis	Red: repeated	n/a: not applicable, not available, not analysed							
Active ingredient	Synthetic or biological product	First international deposit date (indicative)	Foreign patent number	WO	PCT	BR	Patent status in Brazil (in December 2016)	Classification: 1 - (indicative of) primary; 2 - (indicative of) secondary; 3 - (indicative of) primary and secondary	Classification: 1 -product; 2- process; 3 - product and process	
abacavir	synthetic	1990	US5034394; US5089500	WO9100282		n/a	n/a	n/a	n/a	
abacavir	synthetic	1995	-	1995/21161	GB1995000225	PI9506667-5	Expired	2	n/a	
abacavir	synthetic	1995	-	1996/06844	GB1995002014	PI9508629-3	Rejected	2	n/a	
abacavir	synthetic	1996	-	1996/30025	EP1996001352	PI9607851-0	Granted	2	n/a	
abacavir	synthetic	1997	-	1997/49410	EP1997003246	PI9709951-1	Dismissed	2	n/a	
abacavir	synthetic	1998	-	1998/32442	EP1998000197	PI9807523-3	Dismissed	2	n/a	
abacavir	synthetic	1997	US6294540; CA2289753	WO9852949		PI9809124	Dismissed	2	n/a	
abacavir	synthetic	1997	US6294540; CA2289753	WO9852571		PI9809126	Pending	2	n/a	
abacavir	synthetic	1997	US6294540; CA2289753	WO9852570		PI9809127	Dismissed	2	n/a	
abacavir	synthetic	1998	-	1999/32100	JP1998005708	PI9813691-7	n/a	n/a	n/a	
abacavir	synthetic	1998	-	1999/19327	GB1998003080	PI9813048-0	Granted	3	2	
abacavir	synthetic	1998	-	1999/10519	EP1998005291	PI9810472-1	Granted	2	n/a	
abacavir	synthetic	1998	US6641843	WO9939691		PI9907649	Rejected	2	n/a	
abacavir	synthetic	1999	-	WO9955372	EP1999002794	PI9910071	Dismissed	2	n/a	
abacavir	synthetic	2003	-	2004/002433	SE2003001100	PI0311141-5	Dismissed	2	n/a	
abacavir	synthetic	2004	-	2005/021001	EP2004052028	PI0414027-3	n/a	n/a	n/a	
abacavir	synthetic	2005	-	2006/024667	EP2005054341	PI0514861-8	n/a	n/a	n/a	
abacavir	synthetic	2005	-	2006/024668	EP2005054342	PI0514871-5	n/a	n/a	n/a	
abatacept	biological	1991	-	n/a	n/a	PP1100952	Expired	2	n/a	
abatacept	biological	2001	-	WO_2001_095928	PCT/US2001/018619	PI0110465-9	Rejected	2	n/a	
abatacept	biological	2001	-	WO_2001_092337	PCT/US2001/017139	PI0111191-4	Pending	3	3	
abatacept	biological	2001	-	WO_2002_002638	PCT/US2001/021204	PI0112104-9	Pending	2	n/a	
abatacept	biological	2001	-	WO_2002_002638	PCT/US2001/021204	BR 12 2016 007364 5	Pending	2	n/a	
abatacept	biological	2004	-	WO2005016266	PCT/US2004/024840	PI0413326-9	Pending	2	n/a	
abatacept	biological	2006	-	WO_2006_108035	PCT/US2006/012648	PI0608144-4	Pending	2	n/a	
abatacept	biological	2006	CA 2634547	WO2007076032	PCT/US2006/049074	PI0620178-4	Pending	2	n/a	
abatacept	biological	2006	CA 2634547	WO2007076032	PCT/US2006/049074	PI0622251-0	Pending	2	n/a	
abatacept	biological	2006	CA 2634547	WO2007076354	PCT/US2006/062297	PI0620186-5	Pending	2	n/a	
abatacept	biological	2006	CA 2634547	WO2007076354	PCT/US2006/062297	PI0622256-0	Pending	2	n/a	
abatacept	biological	2007	-	WO2007109052	PCT/US2007/006443	PI0708902-3	Dismissed	n/a	n/a	
abatacept	biological	2007	-	WO_2007_087521	PCT/US2007/060893	n/a	n/a	n/a	n/a	
abatacept	biological	2007	-	WO_2007_134147	PCT/US2007/068631	n/a	n/a	n/a	n/a	
abatacept	biological	2007	-	WO_2008_014035	PCT/US2007/068348	n/a	n/a	n/a	n/a	

Supplemental File: Medicines under exclusivity situation funded by the Ministry of Health: analysis of the patent situation and public procurement. Gabriela Costa Chaves, et al. Fiocruz.

abatacept	biological	2008	-	WO_2009_058564	PCT/US2008/079981	PI 0819134-4	Pending	3	3
abatacept	biological	2009	-	WO_2009_137424	PCT/US2009/042761	PI 0912249-4	Pending	2	n/a
abatacept	biological	2009	-	WO_2010_033854	PCT/US2009/057552	n/a	n/a	n/a	n/a
abatacept	biological	2010	-	WO_2010_136492	PCT/EP2010/057246	PI 1013807-2	Pending	2	n/a
abatacept	biological	2010	-	WO_2011_044180	PCT/US2010/051552	BR 11 2012 007854 2	Pending	2	n/a
abatacept	biological	2010	-	WO_2011_017294	PCT/US2010/044206	n/a	n/a	n/a	n/a
abatacept	biological	2011	-	WO_2012_033953	PCT/US2011/050891	n/a	n/a	n/a	n/a
abatacept	biological	2011	-	WO_2013_010537	PCT/DK2011/050289	n/a	n/a	n/a	n/a
abatacept	biological	2013	-	WO_2013_169338	PCT/US2013/030179	BR 11 2014 026718 9	Pending	2	n/a
abatacept	biological	2015	-	WO_2015_164595	PCT/US2015/027281	BR 11 2016 023450 2	Pending	2	n/a
abatacept	biological	2016	-	WO_2016_142532	PCT/EP2016/055332	BR 11 2017 018224 6	Pending	2	n/a
abatacept	biological	2016	-	WO_2016_156476	PCT/EP2016/057036	n/a	n/a	n/a	n/a
abiraterone	synthetic	1993	-	WO1993020097	PCT/GB1993/000531	n/a	n/a	n/a	n/a
abiraterone	synthetic	2007	US8822438; US2011144016; US2016151394; CA2661422	WO2008024484	PCT/US2007/018769	n/a	n/a	n/a	n/a
abiraterone	synthetic	2008	-	WO 2009009132	PCT/US2008/008540	n/a	n/a	n/a	n/a
abiraterone	synthetic	2012	-	WO 2012135759	PCT/US2012/031679	BR 11 2013 025355 0	n/a	n/a	n/a
abiraterone	synthetic	2012	-	WO 2014071983	PCT/EP2012/072207	n/a	n/a	n/a	n/a
abiraterone	synthetic	2012	-	WO 2014071984	PCT/EP2012/072208	n/a	n/a	n/a	n/a
abiraterone	synthetic	2013	-	WO 2013184621	PCT/US2013/043989	BR 11 2014 030099 2	n/a	n/a	n/a
abiraterone	synthetic	2013	-	WO 2014009436	PCT/EP2013/064620	n/a	n/a	n/a	n/a
abiraterone	synthetic	2013	-	WO 2014009437	PCT/EP2013/064622	n/a	n/a	n/a	n/a
abiraterone	synthetic	2013	-	WO 2014095833	PCT/EP2013/076865	n/a	n/a	n/a	n/a
abiraterone	synthetic	2013	-	WO 2014100403	PCT/US2013/076534	BR 11 2015 014523 0	Pending	2	n/a
abiraterone	synthetic	2014	CN 103965282	WO 2015161590	PCT/CN2014/084702	n/a	n/a	n/a	n/a
abiraterone	synthetic	2014	-	WO 2014145813	PCT/US2014/030642	BR 11 2015 023629 4	Pending	3	2
abiraterone	synthetic	2014	-	WO 2014207567	PCT/IB2014/002020	n/a	n/a	n/a	n/a
abiraterone	synthetic	2014	-	WO 2015000451	PCT/CZ2014/000073	n/a	n/a	n/a	n/a
abiraterone	synthetic	2014	-	WO 2015032873	PCT/EP2014/068869	n/a	n/a	n/a	n/a
abiraterone	synthetic	2014	-	WO 2015049649	PCT/IB2014/064996	BR 11 2016 006976 5	Pending	2	n/a
abiraterone	synthetic	2014	-	WO 2015086596	PCT/EP2014/077044	n/a	n/a	n/a	n/a
abiraterone	synthetic	2014	US 2014011992	n/a	n/a	n/a	n/a	n/a	n/a
abiraterone	synthetic	2015	-	WO 2015114518	PCT/IB2015/050613	n/a	n/a	n/a	n/a
abiraterone	synthetic	2015	US 2015246060	WO2016044701	PCT/US2015/050889	n/a	n/a	n/a	n/a
abiraterone	synthetic	2015	CN 104558091	n/a	n/a	n/a	n/a	n/a	n/a
abiraterone	synthetic	2015	CN 105017371	n/a	n/a	n/a	n/a	n/a	n/a
abiraterone	synthetic	2015	US 2015246060	WO2016044701	PCT/US2015/050889	n/a	n/a	n/a	n/a
abiraterone	synthetic	2015	-	WO 2015114518	PCT/IB2015/050613	n/a	n/a	n/a	n/a
abiraterone	synthetic	2015	US 2015246060	WO2016044701	PCT/US2015/050889	n/a	n/a	n/a	n/a
abiraterone	synthetic	2015	CN 105017371	n/a	n/a	n/a	n/a	n/a	n/a
abiraterone	synthetic	2015	-	WO 2016004910	PCT/CZ2015/000075	n/a	n/a	n/a	n/a
abiraterone	synthetic	2016	CN 105267224	n/a	n/a	n/a	n/a	n/a	n/a

Supplemental File: Medicines under exclusivity situation funded by the Ministry of Health: analysis of the patent situation and public procurement. Gabriela Costa Chaves, et al. Fiocruz.

abiraterone	synthetic	2016	CN 105461777	n/a	n/a	n/a	n/a	n/a	n/a
adalimumab	biological	1997	-	1997/029131	US1997002219	PI9707379-2	Granted	3	1
adalimumab	biological	1997	-	1997/029131	US1997002219	PI9715219-6	Granted	3	2
adalimumab	biological	1997	-	1997/029131	US1997002219	PI9715284-6	Pending	3	3
adalimumab	biological	2001	-	WO_2002_030986	US2001032140	PI0114646-7	n/a	n/a	n/a
adalimumab	biological	2001	-	WO_2002_048376	US2001047581	PI0116680-8	Rejected	3	2
adalimumab	biological	2002	CA2385745	WO02100330	PCT/US2002/017790	PI0206289	Pending	2	n/a
adalimumab	biological	2002	CA2385745	WO02100330	PCT/US2002/017790	BR 12 2017 003375 1	Pending	2	n/a
adalimumab	biological	2002	-	WO_2002_102854	IB2002003523	n/a	n/a	n/a	n/a
adalimumab	biological	2003	-	WO2004004633	US2003012976	PI0306444	Dismissed	2	n/a
adalimumab	biological	2003	-	WO_2003_070760	PCT/EP2003/001759	PI0307837	Pending	3	3
adalimumab	biological	2003	CA2494756	WO2004016286	PCT/IB2003/004502	PI0313492	Pending	2	n/a
adalimumab	biological	2003	CA2504868; CA2847142	WO2004009776	PCT/US2003/022566	PI0312785	Pending	2	n/a
adalimumab	biological	2003	CA2504868; CA2847142	WO2004037205	PCT/US2003/033973	PI0315597	Dismissed	2	n/a
adalimumab	biological	2003	-	WO2004050847	US2003038198	PI0316643	Dismissed	3	2
adalimumab	biological	2004	-	WO2004105798	SE2004000817	PI0410739	Dismissed	2	n/a
adalimumab	biological	2004	-	WO_2004_065417	US2004001844	n/a	n/a	n/a	n/a
adalimumab	biological	2004	-	WO_2005_050200	US2004036651	PI0416305-2	n/a	n/a	n/a
adalimumab	biological	2005	-	WO_2005_097832	PCT/US2005/010994	PI0508761-9	Pending	3	3
adalimumab	biological	2005	CA2504868; CA2847142	WO2005110452	PCT/US2005/012007	PI0509326	Pending	2	n/a
adalimumab	biological	2005	-	2006/000785	GB2005002487	PI0512554-5	n/a	n/a	n/a
adalimumab	biological	2005	CA2504868; CA2847142	WO2005110452	PCT/US2005/012007	BR 12 2015 032703 2	Pending	2	n/a
adalimumab	biological	2006	CA2504868; CA2847142	WO2006125229	PCT/US2006/019982	PI0610058	Pending	2	n/a
adalimumab	biological	2006	-	WO2007014162	US2006028691	PI0613784	Dismissed	2	n/a
adalimumab	biological	2006	-	2007/024715	US2006032398	PI0615026-8	n/a	n/a	n/a
adalimumab	biological	2006	-	2007/089303	US2006042564	PI0618085-0	n/a	n/a	n/a
adalimumab	biological	2006	-	WO2007080277	FR2006002748	PI0619726	Dismissed	1	2
adalimumab	biological	2005	-	WO_2006_001179	JP2005/010607	n/a	n/a	n/a	n/a
adalimumab	biological	2007	CA2898529	WO2007120626	PCT/US2007/008787	n/a	n/a	n/a	n/a
adalimumab	biological	2007	CA2898529	WO2007120651	PCT/US2007/008826	n/a	n/a	n/a	n/a
adalimumab	biological	2007	CA2898529	WO2007120656	PCT/US2007/008833	n/a	n/a	n/a	n/a
adalimumab	biological	2007	CA2898529	WO2007120720	PCT/US2007/008962	n/a	n/a	n/a	n/a
adalimumab	biological	2007	CA2898529	WO2007120823	PCT/US2007/009131	n/a	n/a	n/a	n/a
adalimumab	biological	2007	CA2898529	WO2008063213	PCT/US2007/008820	n/a	n/a	n/a	n/a
adalimumab	biological	2007	-	2007/117490	US2007008359	PI0709726-3	Pending	2	n/a
adalimumab	biological	2007	CA2898529	WO2008005315	PCT/US2007/015095	PI0713802	n/a	n/a	n/a
adalimumab	biological	2007	-	2008/057240	US2007022622	PI0717335-0	Dismissed	2	n/a
adalimumab	biological	2007	-	WO_2008_143665	US2007069179	PI0721660-2	n/a	n/a	n/a
adalimumab	biological	2007	-	2008/143666	US2007069185	PI0721707-2	n/a	n/a	n/a
adalimumab	biological	2008	CA2898529	WO2008150490	PCT/US2008/006910	n/a	n/a	n/a	n/a

Supplemental File: Medicines under exclusivity situation funded by the Ministry of Health: analysis of the patent situation and public procurement. Gabriela Costa Chaves, et al. Fiocruz.

adalimumab	biological	2008	-	WO_2009_068649	PCT/EP2008/066438	PI0819693-1	Pending	3	3
adalimumab	biological	2008	CA2904458	WO2009073569	PCT/US2008/085066	PI0819714	Pending	2	n/a
adalimumab	biological	2009	-	2010/141039	US2009061329	PI0920027-4	Pending	2	n/a
adalimumab	biological	2009	-	2010/048192	US2009061338	PI0920572-1	Pending	2	n/a
adalimumab	biological	2010	-	2010/127146	US2010033012	PI1012162-5	n/a	n/a	n/a
adalimumab	biological	2010	-	2010/129469	US2010033387	PI1014446-3	Dismissed	2	n/a
adalimumab	biological	2010	-	WO_2010_097394	EP2010052304	n/a	n/a	n/a	n/a
adalimumab	biological	2010	-	2011/075524	US2010060496	BR 11 2012 014710 2	n/a	n/a	n/a
adalimumab	biological	2011	-	2012/040041	US2011051874	BR 11 2013 006403 0	n/a	n/a	n/a
adalimumab	biological	2011	-	2012/051147	US2011055691	BR 11 2013 008738 2	n/a	n/a	n/a
adalimumab	biological	2011	CA2801917	WO2011153477	PCT/US2011/039135	n/a	n/a	n/a	n/a
adalimumab	biological	2011	CA2815689	WO2012065072	PCT/US2011/060388	BR 11 2013 011699	Pending	2	n/a
adalimumab	biological	2012	-	WO_2013_026833	PCT/EP2012/066215	BR 11 2014 003769 8	Pending	3	3
adalimumab	biological	2011	-	WO_2012_074029	JP2011/077725	n/a	n/a	n/a	n/a
adalimumab	biological	2012	-	2013/055828	US2012059609	BR 11 2014 008730 0	n/a	n/a	n/a
adalimumab	biological	2013	-	2013/130973	US2013028619	BR 11 2014 021644 4	n/a	n/a	n/a
adalimumab	biological	2013	CA2904458	WO2014130064	PCT/US2013/030377	n/a	n/a	n/a	n/a
adalimumab	biological	2013	-	2014/035475	US2013031365	BR 11 2015 004467 0	Pending	2	n/a
adalimumab	biological	2013	-	WO_2014_070939	US2013067591	BR 11 2015 009684 0	Pending	2	n/a
adalimumab	biological	2013	-	WO_2013_164325	EP2013058946	n/a	n/a	n/a	n/a
adalimumab	biological	2014	-	WO_2014_131694	EP2014053378	BR 11 2015 017800 6	Pending	3	3
adalimumab	biological	2014	-	WO_2014_131711	EP2014053489	BR 11 2015 018248 8	Pending	3	3
adalimumab	biological	2014	-	WO_2015_103072	US2014/072336	BR 11 2016 015140	Pending	3	1
adalimumab	biological	2014	-	WO_2014_124457	US2014015861	n/a	n/a	n/a	n/a
adalimumab	biological	2014	-	WO_2015_014979	EP2014066581	n/a	n/a	n/a	n/a
adalimumab	biological	2015	-	WO_2016_026354	CN2015083064	n/a	n/a	n/a	n/a
adefovir	synthetic	1985	US4724233; US4808716	n/a	n/a	n/a	n/a	n/a	n/a
adefovir	synthetic	1990	US5663159	n/a	n/a	PP1100467	Granted	3	1
adefovir	synthetic	1998	US6451340; CA2298057	WO9904774	PCT/US1998/015304	PI9811552	Rejected	2	n/a
adefovir	synthetic	1998	US6451340; CA2298057	WO9904774	PCT/US1998/015304	PI9816303-5	Rejected	2	n/a
adefovir	synthetic	1999	-	WO0016755	EP1999006886	PI9913791-7	Rejected	2	n/a
adefovir	synthetic	1999	US6635278	WO0035460	PCT/US1999/029626	PI9916820	Pending	2	n/a
aldesleukin	biological	1982	CA 1341633	n/a	n/a	n/a	n/a	n/a	n/a
aldesleukin	biological	1982	EP 0109748	n/a	n/a	n/a	n/a	n/a	n/a
aldesleukin	biological	1985	US 4530787	n/a	n/a	n/a	n/a	n/a	n/a
aldesleukin	biological	1985	-	WO 1985004328	PCT/US1985/000501	n/a	n/a	n/a	n/a
aldesleukin	biological	1984	-	WO_1985_000817	US1984001252	n/a	n/a	n/a	n/a
aldesleukin	biological	1986	US 4569790	n/a	n/a	n/a	n/a	n/a	n/a
aldesleukin	biological	1986	US 4572798	n/a	n/a	n/a	n/a	n/a	n/a
aldesleukin	biological	1986	US 4588585	n/a	n/a	n/a	n/a	n/a	n/a

Supplemental File: Medicines under exclusivity situation funded by the Ministry of Health: analysis of the patent situation and public procurement. Gabriela Costa Chaves, et al. Fiocruz.

aldesleukin	biological	1986	-	WO 1986004606	PCT/US1986/00236	n/a	n/a	n/a	n/a	
aldesleukin	biological	1987	EP 0219979	n/a	n/a	n/a	n/a	n/a	n/a	
aldesleukin	biological	1987	EP 0241242	n/a	n/a	n/a	n/a	n/a	n/a	
aldesleukin	biological	1987	EP 0242233	n/a	n/a	n/a	n/a	n/a	n/a	
aldesleukin	biological	1987	JP 1987242629	n/a	n/a	n/a	n/a	n/a	n/a	
aldesleukin	biological	1988	EP 0256714	n/a	n/a	n/a	n/a	n/a	n/a	
aldesleukin	biological	1988	US 4748234	n/a	n/a	n/a	n/a	n/a	n/a	
aldesleukin	biological	1988	-	WO 1988008849	PCT/US1988/001043	n/a	n/a	n/a	n/a	
aldesleukin	biological	1988	-	WO 1988008850	PCT/US1988/001064	n/a	n/a	n/a	n/a	
aldesleukin	biological	1989	US 4853332	n/a	n/a	n/a	n/a	n/a	n/a	
aldesleukin	biological	1989	-	WO_1990_000565	US1989002917	n/a	n/a	n/a	n/a	
aldesleukin	biological	1991	EP 0426521	n/a	n/a	n/a	n/a	n/a	n/a	
aldesleukin	biological	2001	-	WO 2002034284	PCT/US2001/031903	n/a	n/a	n/a	n/a	
aldesleukin	biological	2000	-	WO_2001_027156	US2000027705	n/a	n/a	n/a	n/a	
aldesleukin	biological	2002	-	WO 2003049694	PCT/US2002/039253	n/a	n/a	n/a	n/a	
aldesleukin	biological	2005	-	WO 2005065719	PCT/CA2005/000040	n/a	n/a	n/a	n/a	
aldesleukin	biological	2004	-	WO_2005_044294	US2004036958	n/a	n/a	n/a	n/a	
aldesleukin	biological	2006	EP 1688146	n/a	n/a	n/a	n/a	n/a	n/a	
aldesleukin	biological	2006	-	WO 2006089150	PCT/US2006/005720	PI0608880	Dismissed	2	n/a	
aldesleukin	biological	2008	-	WO_2009_007244	EP2008058154	n/a	n/a	n/a	n/a	
aldesleukin	biological	2010	-	WO_2010_076339	EP2010050040	n/a	n/a	n/a	n/a	
aldesleukin	biological	2016	-	WO_2016_170176	EP2016059109	BR 11 2017 018368 4	n/a	n/a	n/a	
dornase alfa	biological	1989	-	WO 1990007572	US1989005744	n/a	n/a	n/a	n/a	
dornase alfa	biological	1993	US 5783433; US 2003077267	WO9325670	US1993005136	PI 9306670-8	Rejected	3	2	
dornase alfa	biological	1995	US 2003054532	WO9523854	US1995002457	n/a	n/a	n/a	n/a	
dornase alfa	biological	1995	-	WO 1996001105	US1995008310	n/a	n/a	n/a	n/a	
dornase alfa	biological	1995	US 5457044	n/a	n/a	n/a	n/a	n/a	n/a	
dornase alfa	biological	1995	-	WO_1996_026278	US1995002366	PI 9510323-6	Rejected	3	1	
dornase alfa	biological	1996	-	WO_1996_026279	US1996002421	PI 9607328-4	Rejected	3	1	
dornase alfa	biological	2001	US 6180401	n/a	n/a	n/a	n/a	n/a	n/a	
dornase alfa	biological	2001	US 6284282	n/a	n/a	n/a	n/a	n/a	n/a	
dornase alfa	biological	2001	-	WO_2001_074905	GB2001001324	n/a	n/a	n/a	n/a	
dornase alfa	biological	2002	-	WO_2003_016475	US2002025765	n/a	n/a	n/a	n/a	
dornase alfa	biological	2003	-	WO_2003_099862	NL2003000389	n/a	n/a	n/a	n/a	
dornase alfa	biological	2007	-	WO_2008_021290	US2007017868	n/a	n/a	n/a	n/a	
dornase alfa	biological	2011	-	WO_2012_085144	EP2011073678	n/a	n/a	n/a	n/a	
dornase alfa	biological	2013	-	WO_2013_114374	IL2013050097	BR 11 2014 019117 4	Pending	3	1	
dornase alfa	biological	2013	-	WO_2013_114371	IL2013050094	n/a	n/a	n/a	n/a	
dornase alfa	biological	2013	-	WO_2013_114373	IL2013050096	n/a	n/a	n/a	n/a	
dornase alfa	biological	2013	-	WO_2013_151666	US2013030062	n/a	n/a	n/a	n/a	
dornase alfa	biological	2016	-	WO_2016_108244	IL2016050003	BR 11 2017 014433 6	Pending	3	3	
dornase alfa	biological	2015	-	WO_2016_067944	JP2015079408	n/a	n/a	n/a	n/a	

Supplemental File: Medicines under exclusivity situation funded by the Ministry of Health: analysis of the patent situation and public procurement. Gabriela Costa Chaves, et al. Fiocruz.

dornase alfa	biological	2015	-	WO_2016_040169	US2015048606	n/a	n/a	n/a	n/a	
dornase alfa	biological	2015	-	WO_2016_069889	US2015058039	n/a	n/a	n/a	n/a	
dornase alfa	biological	2016	-	WO_2016_139659	IL2016050229	n/a	n/a	n/a	n/a	
peginterferon alfa-2a	biological	1991	-	n/a	n/a	PI9201015-6	Rejected	2	n/a	
peginterferon alfa-2a	biological	1995	-	n/a	n/a	PI9601276-5	Dismissed	2	n/a	
peginterferon alfa-2a	biological	1997	-	n/a	n/a	PI9703421-5	Granted	3	3	
peginterferon alfa-2a	biological	1998	US2003031647; EP1011714; CA2302834; JP2001516725	WO9913894	PCT/EP1998/005797	PI9812466	Dismissed	2	n/a	
peginterferon alfa-2a	biological	1999	US2003053986; US2005031589; US2007196385; EP1087778; CA2334267; JP2002517451	WO9964016	PCT/EP1999/003746	PI9911076	Rejected	2	n/a	
peginterferon alfa-2a	biological	1999	-	WO_2000_011151	US1999019393	n/a	n/a	n/a	n/a	
peginterferon alfa-2a	biological	2000	US2001046957; EP1220683; CA2380653; JP2003507339	WO_2001012214	PCT/EP2000/007666	PI0013252	Dismissed	2	n/a	
peginterferon alfa-2a	biological	2001	-	WO_2001_095929	US2001041022	PI0111852	Dismissed	2	n/a	
peginterferon alfa-2a	biological	2001	-	WO_2002032414	PCT/US2001/032434	PI0114636	Dismissed	2	n/a	
peginterferon alfa-2a	biological	2001	-	WO_2002_010414	US2001023400	n/a	n/a	n/a	n/a	
peginterferon alfa-2a	biological	2003	EP1562634; JP2006515571	WO2004045648	PCT/EP2003/012498	PI0316227	Dismissed	2	n/a	
peginterferon alfa-2a	biological	2004	-	WO_2004_101797	EP2004005151	n/a	n/a	n/a	n/a	
peginterferon alfa-2a	biological	2004	-	WO_2005_017162	EP2004009067	n/a	n/a	n/a	n/a	
peginterferon alfa-2a	biological	2004	-	WO_2005_017174	EP2004009055	n/a	n/a	n/a	n/a	
peginterferon alfa-2a	biological	2004	-	WO_2005_035768	US2004011968	n/a	n/a	n/a	n/a	
peginterferon alfa-2a	biological	2005	-	WO_2005_120540	IB2005002400	n/a	n/a	n/a	n/a	
peginterferon alfa-2a	biological	2006	-	WO_2007_070392	US2006046942	n/a	n/a	n/a	n/a	
peginterferon alfa-2a	biological	2006	US2007071720; US2008317714; EP1917037; JP2009504706	WO2007020195	PCT/EP2006/065026	PI0614863	Dismissed	2	n/a	
peginterferon alfa-2a	biological	2007	-	WO_2007_092537	US2007003333	n/a	n/a	n/a	n/a	
peginterferon alfa-2a	biological	2007	-	WO_2007_110231	EP2007002700	n/a	n/a	n/a	n/a	
peginterferon alfa-2a	biological	2008	-	WO_2008_155134	EP2008005020	n/a	n/a	n/a	n/a	
peginterferon alfa-2a	biological	2009	-	WO_2011_060583	CN2009075039	n/a	n/a	n/a	n/a	
peginterferon alfa-2a	biological	2009	-	WO_2010_076788	IL2009001223	n/a	n/a	n/a	n/a	
peginterferon alfa-2a	biological	2009	-	WO_2009_100255	US2009033277	n/a	n/a	n/a	n/a	
peginterferon alfa-2a	biological	2009	US9481706; US2013190478; EP2245044; JP2011509963	WO2009090056	PCT/EP2009/000192	PI0906913-5	Dismissed	n/a	n/a	
peginterferon alfa-2a	biological	2009	-	WO/2009/130176	EP2009054641	PI0910534-4	n/a	n/a	n/a	

Supplemental File: Medicines under exclusivity situation funded by the Ministry of Health: analysis of the patent situation and public procurement. Gabriela Costa Chaves, et al. Fiocruz.

peginterferon alfa-2a	biological	2010	US8535887; US2010297080; US2013251677; EP2432898; CN102459647; JP2012527482	WO2010135649	PCT/US2010/035782	n/a	n/a	n/a	n/a	
peginterferon alfa-2a	biological	2010	-	WO_2011_075605	US2010060884	n/a	n/a	n/a	n/a	
peginterferon alfa-2a	biological	2010	-	WO_2012_053691	KR2010008080	n/a	n/a	n/a	n/a	
peginterferon alfa-2a	biological	2010	US2011312513; EP2507636; CN102656459; KR2012085877	WO2011067195	PCT/EP2010/068370	BR 11 2012 011393 3	n/a	n/a	n/a	
peginterferon alfa-2a	biological	2011	-	WO_2011_144756	EP2011058307	BR 11 2012 029577 2	Pending	2	n/a	
peginterferon alfa-2a	biological	2011	US9295669; US2012148533; EP2651414; CN103370066	WO2012080151	PCT/EP2011/072408	BR 11 2013 014642 7	Pending	2	n/a	
peginterferon alfa-2a	biological	2012	US2013078613; EP2694078; CN103491966; KR2014002018	WO 2012130862	EP2012055450	BR 11 2013 024880 7	Pending	2	n/a	
peginterferon alfa-2a	biological	2012	-	WO_2012_175700	EP2012062128	BR 11 2013 032188 1	Pending	2	n/a	
peginterferon alfa-2a	biological	2012	JP 2013512425	WO2012147843	PCT/JP2012/061192	n/a	n/a	n/a	n/a	
peginterferon alfa-2a	biological	2012	JP 2013545772	WO2013076924	PCT/JP2012/007054	n/a	n/a	n/a	n/a	
peginterferon alfa-2a	biological	2012	-	WO_2013_030841	IL2012050345	n/a	n/a	n/a	n/a	
peginterferon alfa-2a	biological	2012	-	WO_2013_069016	IL2012050448	n/a	n/a	n/a	n/a	
peginterferon alfa-2a	biological	2014	-	WO_2014_128701	IL2014050178	n/a	n/a	n/a	n/a	
peginterferon alfa-2a	biological	2014	-	WO/2015/059303	EP2014072919	BR 11 2016 008973 1	n/a	n/a	n/a	
peginterferon alfa-2a	biological	2014	US2016298194; EP3083991; CN105829548; KR2016091354	WO2015091306	PCT/EP2014/077667	BR 11 2016 013921 6	n/a	n/a	n/a	
peginterferon alfa-2a	biological	2014	US2016298194; EP3083991; CN105829548; KR2016091354	WO2015092599	PCT/IB2014/066633	n/a	n/a	n/a	n/a	
peginterferon alfa-2a	biological	2014	-	WO_2015_059701_A1	IL2014050917	n/a	n/a	n/a	n/a	
peginterferon alfa-2a	biological	2014	-	WO_2015_063769_A1	PCT/IL2014/050941	n/a	n/a	n/a	n/a	
peginterferon alfa-2a	biological	2015	-	WO_2015_155370_A1	PCT/EP2015/057994	n/a	n/a	n/a	n/a	
peginterferon alfa-2a	biological	2015	-	WO2016011055	PCT/US2015/040413	n/a	n/a	n/a	n/a	
peginterferon alfa-2a	biological	2015	JP 2017528526	WO2016082732	PCT/CN2015/095341	n/a	n/a	n/a	n/a	
peginterferon alfa-2a	biological	2015	EP 3200767	WO2016046101	PCT/EP2015/071536	n/a	n/a	n/a	n/a	
peginterferon alfa-2a	biological	2015	US2017283889; EP3234181; CN107002149	WO2016096800	PCT/EP2015/079719	n/a	n/a	n/a	n/a	
peginterferon alfa-2a	biological	2015	-	WO_2016_030489	EP2015069706	n/a	n/a	n/a	n/a	
peginterferon alfa-2a	biological	2015	-	WO_2015_155767	PCT/IL2015/050366	n/a	n/a	n/a	n/a	
peginterferon alfa-2a	biological	2015	-	WO_2015_155766	PCT/IL2015/050363	n/a	n/a	n/a	n/a	
peginterferon alfa-2a	biological	2015	-	WO_2016_097158	PCT/EP2015/080243	n/a	n/a	n/a	n/a	
peginterferon alfa-2a	biological	2016	-	WO 2017009303	PCT/EP2016/066460	n/a	n/a	n/a	n/a	
peginterferon alfa-2a	biological	2016	-	WO 2017076791	PCT/EP2016/076195	n/a	n/a	n/a	n/a	

Supplemental File: Medicines under exclusivity situation funded by the Ministry of Health: analysis of the patent situation and public procurement. Gabriela Costa Chaves, et al. Fiocruz.

peginterferon alfa-2a	biological	2016	-	WO/2016/174200	EP2016059609	BR 11 2017 023171 9	n/a	n/a	n/a	
peginterferon alfa-2b	biological	1980	CA1341567	n/a	n/a	n/a	n/a	n/a	n/a	
peginterferon alfa-2b	biological	1994	CA2268433	WO9513090	PCT/US1994/013207	n/a	n/a	n/a	n/a	
peginterferon alfa-2b	biological	1996	CA2288038	WO9848840	PCT/US1996/017085	n/a	n/a	n/a	n/a	
peginterferon alfa-2b	biological	1996	CA2268433	WO9718832	PCT/US1996/017448	n/a	n/a	n/a	n/a	
peginterferon alfa-2b	biological	1998	CA2268433	WO9932139	PCT/US1998/026677	n/a	n/a	n/a	n/a	
peginterferon alfa-2b	biological	1998	CA2288038	WO9716204	PCT/US1998/007634	PI9809425	Dismissed	2	n/a	
peginterferon alfa-2b	biological	1999	CA2324467	WO9948535	PCT/US1999/004268	PI9909087	Rejected	2	n/a	
peginterferon alfa-2b	biological	1999	CA2324467	WO9948535	PCT/US1999/004268	PI9917815	Pending	2	n/a	
peginterferon alfa-2b	biological	2000	-	00/61173	US2000009038	PI0009642	Dismissed	2	n/a	
peginterferon alfa-2b	biological	2000	-	00/61174	US2000009127	PI0009644	Rejected	2	n/a	
peginterferon alfa-2b	biological	2000	-	2000/061175	US2000009129	PI0009646	Rejected	2	n/a	
peginterferon alfa-2b	biological	2001	-	01/66132	US2001007453	PI0108997	Dismissed	2	n/a	
peginterferon alfa-2b	biological	2005	-	2006/020720	US2005028441	PI0513332	Dismissed	2	n/a	
peginterferon alfa-2b	biological	2009	-	WO_2009_130176	PCT/EP2009/054641	PI0910534-4	Dismissed	2	n/a	
peginterferon alfa-2b	biological	2014	-	WO_2015_059303	PCT/EP2014/072919	BR 11 2016 008973	Pending	2	n/a	
peginterferon alfa-2b	biological	2016	-	WO_2016_174200	PCT/EP2016/059609	BR 11 2017 023171	Pending	2	n/a	
alphavelaglycerase	biological	2000	-	WO_2001_049830	PCT/DK2000/000743	n/a	n/a	n/a	n/a	
alphavelaglycerase	biological	2000	-	WO_2001_049830	PCT/DK2000/000743	n/a	n/a	n/a	n/a	
alphavelaglycerase	biological	2011	-	WO_2011_107991	PCT/IL2011/000210	n/a	n/a	n/a	n/a	
alphavelaglycerase	biological	2001	CA2767473	WO2002015927	PCT/US2001/025882	n/a	n/a	n/a	n/a	
alphavelaglycerase	biological	2005	-	WO_2005_115429	PCT/IL2005/000530	n/a	n/a	n/a	n/a	
alphavelaglycerase	biological	2007	-	WO_2007_126546	PCT/US2007/005711	n/a	n/a	n/a	n/a	
alphavelaglycerase	biological	2007	-	WO_2007_146038	PCT/US2007/013383	PI 0712383-3	Pending	2	n/a	
alphavelaglycerase	biological	2007	CA2641588	WO2007092829	PCT/US2007/061657	n/a	n/a	n/a	n/a	
alphavelaglycerase	biological	2009	-	WO_2009_104176	PCT/IL2009/000171	n/a	n/a	n/a	n/a	
alphavelaglycerase	biological	2009	-	WO_2010_006215	PCT/US2009/050174	n/a	n/a	n/a	n/a	
alphavelaglycerase	biological	2010	US2014242061; US2011027254	WO2011017177	PCT/US2010/043586	BR 11 2012 002076 5	Pending	2	n/a	
alphavelaglycerase	biological	2001	-	WO_2001_077307	PCT/US2001/011144	n/a	n/a	n/a	n/a	
alphavelaglycerase	biological	2011	-	WO_2012_064709	PCT/US2011/059731	BR 11 2013 011152 6	Pending	2	n/a	
alphavelaglycerase	biological	2012	-	WO_2012_098111	PCT/EP2012/050630	n/a	n/a	n/a	n/a	
alphavelaglycerase	biological	2013	-	WO2013130963	PCT/US2013/028608	n/a	n/a	n/a	n/a	
alphavelaglycerase	biological	2013	-	WO_2013_121405	PCT/IB2013/051346	BR 11 2014 021067 5	Pending	2	n/a	
alphavelaglycerase	biological	2013	-	WO_2014_071282	PCT/US2013/068242	BR 11 2015 009746 4	Pending	2	n/a	
alphavelaglycerase	biological	2015	-	WO_2015_118547	PCT/IL2015/050145	n/a	n/a	n/a	n/a	
alphavelaglycerase	biological	2009	-	WO_2010_006215	PCT/US2009/050174	n/a	n/a	n/a	n/a	
alphavelaglycerase	biological	2015	-	WO_2015_157117	PCT/US2015/024310	n/a	n/a	n/a	n/a	
alphavelaglycerase	biological	2010	-	WO_2010_080720	PCT/US2010/000078	n/a	n/a	n/a	n/a	
alphavelaglycerase	biological	2016	-	WO_2016_146760	PCT/EP2016/055830	BR 11 2017 015348 3	Pending	3	2	
ambrisentan	synthetic	1994	US5703017	WO199425442	EP1994001141	PI9406478	Dismissed	2	n/a	

Supplemental File: Medicines under exclusivity situation funded by the Ministry of Health: analysis of the patent situation and public procurement. Gabriela Costa Chaves, et al. Fiocruz.

ambrisentan	synthetic	1995	US5840722	WO199526716	EP1995001099	PI9507231	Dismissed	2	n/a	
ambrisentan	synthetic	1995	USRE42462; US5932730; US7109205; US7601730	WO199611914	EP1995003963	PI9509338	Dismissed	2	n/a	
ambrisentan	synthetic	2007	US8377933; US9474752; CA2669536	WO2008073928	US2007087058	n/a	n/a	n/a	n/a	
ambrisentan	synthetic	2011	US9549926; CA2814518	WO2012051559	US2011056404	BR112013008983	Pending	2	n/a	
bevacizumab	biological	1992	-	94/10202	US1992009218	PI9207175	Dismissed	2	n/a	
bevacizumab	biological	1993	-	n/a	n/a	PP1101137	n/a	n/a	n/a	
bevacizumab	biological	1998	CA2286330	WO9845331	PCT/US1998/006604	PI9809387	Granted	2	n/a	
bevacizumab	biological	1998	CA2286330	WO9845331	PCT/US1998/006604	PI9816306-0	Rejected	2	n/a	
bevacizumab	biological	1998	CA2286330	WO9845331	PCT/US1998/006604	PI9816350-7	Pending	3	3	
bevacizumab	biological	1998	CA2286330	WO9845332	PCT/US1998/006724	PI9809388	Rejected	3	3	
bevacizumab	biological	2001	-	WO_2002_061090	PCT/US2001/048691	n/a	n/a	n/a	n/a	
bevacizumab	biological	2003	-	2003/068260	JP2003001563	PI0307702-0	n/a	n/a	n/a	
bevacizumab	biological	2004	-	2005/000900	US2004017078	PI0411200-8	Pending	2	n/a	
bevacizumab	biological	2005	-	2006/012500	US2005026017	PI0513601-6	n/a	n/a	n/a	
bevacizumab	biological	2005	-	2006/044908	US2005037471	PI0516299-8	Pending	3	2	
bevacizumab	biological	2005	-	2006/066086	US2005045600	PI0518105	Dismissed	2	n/a	
bevacizumab	biological	2007	-	2008/073509	US2007068300	PI0717688	Pending	2	n/a	
bevacizumab	biological	2007	-	2008/077077	US2007088000	PI0720552-0	Pending	2	n/a	
bevacizumab	biological	2008	-	2009/058812	US2008081516	PI0817182-3	Pending	2	n/a	
bevacizumab	biological	2009	-	2010/059969	US2009065381	PI0916138-4	Pending	2	n/a	
bevacizumab	biological	2009	-	WO_2010_040508	PCT/EP2009/007182	PI0919663-3	Pending	3	3	
bevacizumab	biological	2010	-	2011/084750	US2010061347	BR 11 2012 013093 5	Pending	2	n/a	
bevacizumab	biological	2011	-	2011/089101	EP2011050564	BR 11 2012 016229 2	Pending	2	n/a	
bevacizumab	biological	2010	CA2787952	WO2011106300	PCT/US1998/006724	BR 11 2012 020700	Pending	2	n/a	
bevacizumab	biological	2010	-	WO_2010_136482	PCT/EP2010/057229	n/a	n/a	n/a	n/a	
bevacizumab	biological	2011	-	WO_2011_117329	PCT/EP2011/054504	BR 11 2012 024287 3	Pending	3	3	
bevacizumab	biological	2011	-	WO_2011_117330	PCT/EP2011/054505	BR 11 2012 024312 8	Pending	3	3	
bevacizumab	biological	2011	-	2012/010546	EP2011062226	BR 11 2012 033423 9	Pending	2	n/a	
bevacizumab	biological	2011	-	2012/020123	EP2011063932	BR 11 2013 001879 8	Pending	2	n/a	
bevacizumab	biological	2011	-	2012/076582	EP2011072026	BR 11 2013 014195 6	Pending	2	n/a	
bevacizumab	biological	2011	-	WO_2011_104307	PCT/EP2011/052758	n/a	n/a	n/a	n/a	
bevacizumab	biological	2011	-	WO_2011_109789	PCT/US2011/027317	n/a	n/a	n/a	n/a	
bevacizumab	biological	2011	-	WO_2012_039756	PCT/US2011/001618	n/a	n/a	n/a	n/a	
bevacizumab	biological	2012	-	WO_2013_087789	PCT/EP2012/075434	n/a	n/a	n/a	n/a	
bevacizumab	biological	2012	-	WO_2013_070565	PCT/US2012/063639	n/a	n/a	n/a	n/a	
bevacizumab	biological	2013	-	WO_2013_173687	PCT/US2013/041532	BR 11 2014 028600 0	Pending	2	n/a	
bevacizumab	biological	2013	-	WO_2014_071212	PCT/US2013/068110	BR 11 2015 009924 6	Pending	2	n/a	
bevacizumab	biological	2013	-	WO_2014_085654	PCT/US2013/072335	BR 11 2015 012538 7	Pending	3	3	
bevacizumab	biological	2013	-	WO_2014_096551	PCT/FI2013/051193	n/a	n/a	n/a	n/a	

Supplemental File: Medicines under exclusivity situation funded by the Ministry of Health: analysis of the patent situation and public procurement. Gabriela Costa Chaves, et al. Fiocruz.

bevacizumab	biological	2014	-	WO_2014_177771	PCT/FI2014/050322	n/a	n/a	n/a	n/a	
bevacizumab	biological	2014	-	WO_2015_005632	PCT/KR2014/006090	n/a	n/a	n/a	n/a	
bevacizumab	biological	2014	-	WO_2015_063180	PCT/EP2014/073261	n/a	n/a	n/a	n/a	
bevacizumab	biological	2014	-	WO_2015_038669	PCT/US2014/055028	n/a	n/a	n/a	n/a	
bevacizumab	biological	2014	-	WO_2015_091655	PCT/EP2014/078233	BR 11 2016 007112 3	Pending	2	n/a	
bevacizumab	biological	2014	-	WO_2015_053523	PCT/KR2014/009398	BR 11 2016 007547 1	Pending	3	2	
bevacizumab	biological	2015	-	WO_2016_005931	PCT/IB2015/055189	BR 11 2017 000389 9	Pending	3	2	
bevacizumab	biological	2015	-	WO_2016_075035	PCT/EP2015/075876	BR 11 2017 009790 7	Pending	2	n/a	
bevacizumab	biological	2015	-	WO_2016_079739	PCT/IL2015/051112	BR 11 2017 010555 1	Pending	3	2	
bevacizumab	biological	2015	-	WO_2015_148984	PCT/US2015/023108	n/a	n/a	n/a	n/a	
bevacizumab	biological	2015	-	WO_2016_073894	PCT/US2015/059539	n/a	n/a	n/a	n/a	
bevacizumab	biological	2016	-	WO_2016_170040	PCT/EP2016/058870	n/a	n/a	n/a	n/a	
bevacizumab	biological	2016	-	WO_2016_170039	PCT/EP2016/058870	n/a	n/a	n/a	n/a	
bromocriptine	synthetic	1969	US3752888	n/a	n/a	n/a	n/a	n/a	n/a	
bromocriptine	synthetic	1973	US3752814	n/a	n/a	n/a	n/a	n/a	n/a	
bromocriptine	synthetic	1992	US5468755; US5679685; US5716957; US5756513; US5866584	WO9300092	PCT/US1992/005074	PI9206190	Rejected	2	n/a	
bromocriptine	synthetic	1992	US5468755; US5679685; US5716957; US5756513; US5866584	WO9312793	PCT/US1992/011166	n/a	n/a	n/a	n/a	
bromocriptine	synthetic	1993	US5468755; US5679685; US5716957; US5756513; US5866584	WO9415211	PCT/US1993/012701	n/a	n/a	n/a	n/a	
bromocriptine	synthetic	1994	US5468755; US5679685; US5716957; US5756513; US5866584	WO9517170	PCT/US1994/014994	n/a	n/a	n/a	n/a	
bromocriptine	synthetic	1995	US5468755; US5679685; US5716957; US5756513; US5866584	WO9518614	PCT/US1995/000663	n/a	n/a	n/a	n/a	
bromocriptine	synthetic	1995	US5468755; US5679685; US5716957; US5756513; US5866584	WO9535110	PCT/US1995/009056	n/a	n/a	n/a	n/a	
bromocriptine	synthetic	1995	US5468755; US5679685; US5716957; US5756513; US5866584	WO9601561	PCT/US1995/009419	PI9507858	Dismissed	2	n/a	

Supplemental File: Medicines under exclusivity situation funded by the Ministry of Health: analysis of the patent situation and public procurement. Gabriela Costa Chaves, et al. Fiocruz.

bromocriptine	synthetic	1995	US5468755; US5679685; US5716957; US5756513; US5866584	WO9600396	PCT/US1995/009061	PI9508366	Dismissed	2	n/a	
bromocriptine	synthetic	2004	US7888310	n/a	n/a	n/a	n/a	n/a	n/a	
bromocriptine	synthetic	2009	US7888310	n/a	n/a	n/a	n/a	n/a	n/a	
bromocriptine	synthetic	2010	US8877708; US9352025	WO2010141938	PCT/US2010/037605	PI1009619	Pending	2	n/a	
bromocriptine	synthetic	2011	US8137992	n/a	n/a	n/a	n/a	n/a	n/a	
bromocriptine	synthetic	2011	US8137993	n/a	n/a	n/a	n/a	n/a	n/a	
bromocriptine	synthetic	2011	US8137994	n/a	n/a	n/a	n/a	n/a	n/a	
bromocriptine	synthetic	2012	US8431155; US8613947; US9192576; US9522117	WO2013165902	PCT/US2013/038655	BR 11 2014 027087 2	Pending	2	n/a	
certolizumab	biological	2001	CA 2380298	WO 200194585	PCT/GB2001/002477	PI 0106682	Pending	3	3	
certolizumab	biological	2002	-	WO_2003_031475	PCT/GB2002/004619	PI 0212756-3	Dismissed	n/a	n/a	
certolizumab	biological	2002	-	WO 2003045400	IB2002004367	PI 0214810-2	n/a	n/a	n/a	
certolizumab	biological	2003	-	WO 2004019861	US2003024414	n/a	n/a	n/a	n/a	
certolizumab	biological	2003	-	WO 2004019860	US2003024413	n/a	n/a	n/a	n/a	
certolizumab	biological	2003	-	WO 2004053064	US2003038499	n/a	n/a	n/a	n/a	
certolizumab	biological	2004	-	WO 2004067006	IB2004000616	n/a	n/a	n/a	n/a	
certolizumab	biological	2004	-	WO 2004071527	EP2004001142	n/a	n/a	n/a	n/a	
certolizumab	biological	2004	-	WO 2004098578	EP2004050750	n/a	n/a	n/a	n/a	
certolizumab	biological	2004	-	WO 2005014649	IB2004002529	n/a	n/a	n/a	n/a	
certolizumab	biological	2004	-	WO_2005_012359	PCT/US2004/024662	PI 0412637-8	Pending	3	3	
certolizumab	biological	2004	-	WO_2005_044853	PCT/US2004/029332	n/a	n/a	n/a	n/a	
certolizumab	biological	2005	-	WO 2005123772	IL2005000638	n/a	n/a	n/a	n/a	
certolizumab	biological	2006	-	WO_2007_039714	PCT/GB2006/003640	n/a	n/a	n/a	n/a	
certolizumab	biological	2010	-	WO_2010_114940	PCT/US2010/029521	PI 1012560-4	Pending	3	3	
certolizumab	biological	2007	-	WO_2008_079849	PCT/US2007/088061	n/a	n/a	n/a	n/a	
certolizumab	biological	2008	-	WO_2009_073805_A2	PCT/US2008/085568	n/a	n/a	n/a	n/a	
certolizumab	biological	2010	-	WO_2011_036454	PCT/GB2010/001790	BR 11 2012 006670 6	Pending	3	2	
certolizumab	biological	2010	-	WO 2011056590	US2010054125	BR 11 2012 009855	n/a	n/a	n/a	
certolizumab	biological	2010	-	WO_2011_036455	PCT/GB2010/001792	n/a	n/a	n/a	n/a	
certolizumab	biological	2011	-	WO_2011_086141	PCT/EP2011/050418	n/a	n/a	n/a	n/a	
certolizumab	biological	2011	-	WO_2012_054438	PCT/US2011/056649	n/a	n/a	n/a	n/a	
certolizumab	biological	2011	-	WO_2012_006341	PCT/US2011/043056	n/a	n/a	n/a	n/a	
certolizumab	biological	2011	-	WO 2012061620	US2011059195	n/a	n/a	n/a	n/a	
certolizumab	biological	2011	-	WO_2011_086138	PCT/EP2011/050415	BR 11 2012 016807 0	Pending	3	2	
certolizumab	biological	2011	-	WO_2011_086139	PCT/EP2011/050416	BR 11 2012 016808 8	Pending	3	2	
certolizumab	biological	2011	-	WO_2011_086136	PCT/EP2011/050413	BR 11 2012 017425 8	Pending	3	2	
certolizumab	biological	2011	-	WO_2011_107480	PCT/EP2011/053038	BR 11 2012 021926 0	Pending	3	3	
certolizumab	biological	2011	-	WO_2011_149999	PCT/US2011/037826	BR 11 2012 030179 9	Pending	3	3	

Supplemental File: Medicines under exclusivity situation funded by the Ministry of Health: analysis of the patent situation and public procurement. Gabriela Costa Chaves, et al. Fiocruz.

certolizumab	biological	2011	-	WO_2012_013930	PCT/GB2011/001129	BR 11 2013 000177 1	Pending	2	n/a	
certolizumab	biological	2011	-	WO_2012_013682	PCT/EP2011/062837	BR 11 2013 000623 4	Pending	2	n/a	
certolizumab	biological	2011	-	WO_2012_013933	PCT/GB2011/001135	BR 11 2013 001160 2	Pending	2	n/a	
certolizumab	biological	2011	-	WO_2012_069557	PCT/EP2011/070868	BR 11 2013 013003 2	Dismissed	n/a	n/a	
certolizumab	biological	2012	-	WO 2012154987	US2012037375	BR 11 2013 028808 6	n/a	n/a	n/a	
certolizumab	biological	2012	-	WO_2013_011076	PCT/EP2012/064129	BR 11 2014 000341 6	Pending	3	1	
certolizumab	biological	2012	-	WO_2013_019906	PCT/US2012/049233	BR 11 2014 002353 0	Pending	2	n/a	
certolizumab	biological	2012	-	WO_2013_174003	PCT/CN2012/076012	n/a	n/a	n/a	n/a	
certolizumab	biological	2012	-	WO_2012_162277	PCT/US2012/038915	n/a	n/a	n/a	n/a	
certolizumab	biological	2013	-	WO_2013_169609	PCT/US2013/039609	n/a	n/a	n/a	n/a	
certolizumab	biological	2013	-	WO_2014_100689	PCT/US2013/077139	BR 11 2015 014768 2	Pending	3	3	
certolizumab	biological	2014	-	WO_2014_114651	PCT/EP2014/051160	BR 11 2015 017619 4	Pending	2	n/a	
certolizumab	biological	2014	-	WO_2015_009856	PCT/US2014/046896	BR 11 2016 000853 7	Pending	2	n/a	
certolizumab	biological	2014	-	WO_2015_048520	PCT/US2014/057821	BR 11 2016 006397 0	Pending	2	n/a	
certolizumab	biological	2014	-	WO_2015_095410	PCT/US2014/070983	BR 11 2016 013741 8	Pending	2	n/a	
certolizumab	biological	2014	-	WO_2015_095418	PCT/US2014/070992	BR 11 2016 013896 1	Pending	2	n/a	
certolizumab	biological	2014	-	WO_2015_095423	PCT/US2014/070998	BR 11 2016 013963 1	Pending	2	n/a	
certolizumab	biological	2014	-	WO_2015_095404	PCT/US2014/070974	BR 11 2016 013969 0	Pending	2	n/a	
certolizumab	biological	2014	-	WO_2015_054039_A1	PCT/US2014/058937	n/a	n/a	n/a	n/a	
certolizumab	biological	2014	-	WO_2015_073307_A2	PCT/US2014/064458	n/a	n/a	n/a	n/a	
certolizumab	biological	2015	-	WO_2016_011160	PCT/US2015/040582	BR 11 2017 000672 3	Pending	2	n/a	
certolizumab	biological	2015	-	WO_2016_081384	PCT/US2015/060941	BR 11 2017 010198 0	Pending	2	n/a	
certolizumab	biological	2015	-	WO_2016_079050	PCT/EP2015/076682	BR 11 2017 010324 9	Pending	2	n/a	
certolizumab	biological	2015	-	WO_2016_093700	PCT/NL2015/050860	BR 11 2017 012509 9	Pending	3	1	
certolizumab	biological	2015	-	WO_2016_049470	PCT/US2015/052247	n/a	n/a	n/a	n/a	
certolizumab	biological	2015	-	WO_2016_024231	PCT/IB2015/056127	n/a	n/a	n/a	n/a	
certolizumab	biological	2015	-	WO_2016_044189	PCT/US2015/050051	n/a	n/a	n/a	n/a	
certolizumab	biological	2015	-	WO_2016_090300	PCT/US2015/064081	n/a	n/a	n/a	n/a	
certolizumab	biological	2015	-	WO_2016_024228	PCT/IB2015/056123	n/a	n/a	n/a	n/a	
certolizumab	biological	2016	-	WO_2016_149201	PCT/US2016/022345	BR 11 2017 019559 3	Pending	3	3	
certolizumab	biological	2016	-	WO_2016_128912	PCT/IB2016/050704	n/a	n/a	n/a	n/a	
certolizumab	biological	2016	-	WO_2016_183326	PCT/US2016/032112	n/a	n/a	n/a	n/a	
certolizumab	biological	2016	-	WO_2016_191397	PCT/US2016/033840	n/a	n/a	n/a	n/a	
cetuximab	biological	1996	-	WO1996040210	PCT/US1996/009847	n/a	n/a	n/a	n/a	
cetuximab	biological	2002	-	WO2003007988	EP2002006696	PI 0211060-1	Dismissed	2	n/a	
cetuximab	biological	2004	-	WO2005051355	EP2004012837	PI0416968-9	Dismissed	2	n/a	
cetuximab	biological	2004	-	WO 2005058365	EP2004012044	PI 0416986-7	Dismissed	2	n/a	
cetuximab	biological	2004	-	WO_2004_085474	PCT/US2004/008802	n/a	n/a	n/a	n/a	
cetuximab	biological	2005	-	WO 2005077414	EP2005000797	PI 0507608-0	n/a	n/a	n/a	
cetuximab	biological	2005	-	WO 2005089372	US2005008733	n/a	n/a	n/a	n/a	
cetuximab	biological	2008	-	WO 2008148546	EP2008004456	PI 0812777-8	n/a	n/a	n/a	
cetuximab	biological	2008	-	WO_2008_135259	PCT/EP2008/003586	n/a	n/a	n/a	n/a	
cetuximab	biological	2009	-	WO_2009_107129	PCT/IL2009/000211	n/a	n/a	n/a	n/a	

Supplemental File: Medicines under exclusivity situation funded by the Ministry of Health: analysis of the patent situation and public procurement. Gabriela Costa Chaves, et al. Fiocruz.

cetuximab	biological	2010	US 2010247533	WO2010112413	EP2010053973	PI1012619-8	Expired	2	n/a	
cetuximab	biological	2011	-	WO_2012_025525	PCT/EP2011/064468	BR 11 2013 002167 5	Pending	3	1	
cetuximab	biological	2011	-	WO 2012022724	EP2011064050	BR 11 2013 003530-7	n/a	n/a	n/a	
cetuximab	biological	2011	-	WO 2012022677	EP2011063892	BR 11 2013 003532 3	n/a	n/a	n/a	
cetuximab	biological	2011	-	WO_2012_073985	PCT/JP2011/077603	BR 11 2013 013311 2	Pending	3	3	
cetuximab	biological	2011	-	WO 2012076688	EP2011072310	n/a	n/a	n/a	n/a	
cetuximab	biological	2012	-	WO 2013018018	IB2012053881	n/a	n/a	n/a	n/a	
cetuximab	biological	2012	-	WO 2013023043	US2012050124	n/a	n/a	n/a	n/a	
cetuximab	biological	2012	-	WO 2013068103	EP2012004627	n/a	n/a	n/a	n/a	
cetuximab	biological	2012	-	WO_2012_131555	PCT/IB2012/051410	BR 11 2013 023918 2	Pending	1	1	
cetuximab	biological	2012	-	WO_2013_092001	PCT/EP2012/072364	BR 11 2014 015018 4	Pending	3	3	
cetuximab	biological	2013	-	WO_2013_134743	PCT/US2013/030055	BR 11 2014 022228 2	Pending	3	3	
cetuximab	biological	2013	-	WO_2014_004694	PCT/US2013/047932	n/a	n/a	n/a	n/a	
cetuximab	biological	2013	-	WO 2013139423	EP2013000495	BR 11 2014 022266 5	n/a	n/a	n/a	
cetuximab	biological	2013	-	WO 2014025688	US2013053619	BR 11 2015 002384 3	n/a	n/a	n/a	
cetuximab	biological	2014	-	WO_2014_125382	PCT/IB2014/000867	BR 11 2015 019339 0	Pending	3	3	
cetuximab	biological	2014	-	WO_2015_013671	PCT/US2014/048289	BR 11 2016 001611 4	Pending	3	3	
cetuximab	biological	2014	-	WO_2015_038984	PCT/US2014/055526	BR 11 2016 005526 8	Pending	3	1	
cetuximab	biological	2014	-	WO_2015_048329	PCT/US2014/057523	BR 11 2016 006665 0	Pending	1	1	
cetuximab	biological	2014	-	WO_2015_063339	PCT/EP2014/073738	BR 11 2016 009919 2	Pending	1	3	
cetuximab	biological	2014	-	WO_2015_096982	PCT/EP2014/077144	BR 11 2016 014830 4	Pending	2	n/a	
cetuximab	biological	2014	-	WO_2015_089283	PCT/US2014/069747	n/a	n/a	n/a	n/a	
cetuximab	biological	2015	-	WO_2015_116933	PCT/US2015/013776	BR 11 2016 017649 9	Pending	3	3	
cetuximab	biological	2015	-	WO_2015_181805	PCT/IB2015/054107	BR 11 2016 027888 7	Pending	3	3	
cetuximab	biological	2015	-	WO 2016011956	CN2015084886	BR 11 2017 001165 4	n/a	n/a	n/a	
cetuximab	biological	2015	-	WO_2016_071004	PCT/EP2015/060003	BR 11 2017 009264 6	Pending	1	1	
cetuximab	biological	2015	-	WO 2016059600	IB2015057940	n/a	n/a	n/a	n/a	
cetuximab	biological	2015	-	WO_2016_023909	PCT/EP2015/068482	n/a	n/a	n/a	n/a	
cetuximab	biological	2015	-	WO_2016_106157	PCT/US2015/066951	n/a	n/a	n/a	n/a	
cetuximab	biological	2015	-	WO_2016_004383	PCT/US2015/039103	n/a	n/a	n/a	n/a	
cetuximab	biological	2015	-	WO_2015_104406	PCT/EP2015/050378	n/a	n/a	n/a	n/a	
cetuximab	biological	2015	-	WO_2016_023909	PCT/EP2015/068482	n/a	n/a	n/a	n/a	
cetuximab	biological	2015	-	WO_2015_189478	PCT/FI2015/050423	n/a	n/a	n/a	n/a	
cetuximab	biological	2015	-	WO_2015_189477	PCT/FI2015/050422	n/a	n/a	n/a	n/a	
cetuximab	biological	2015	-	WO_2015_153765	PCT/US2015/023888	n/a	n/a	n/a	n/a	
cetuximab	biological	2015	-	WO 2015121465	EP2015053196	n/a	n/a	n/a	n/a	
cetuximab	biological	2015	-	WO 2015145388	IB2015052245	n/a	n/a	n/a	n/a	
cetuximab	biological	2016	-	WO_2016_118629	PCT/US2016/014132	BR 11 2017 015468 4	Pending	3	3	
cetuximab	biological	2016	-	WO_2016_124670	PCT/EP2016/052345	n/a	n/a	n/a	n/a	
cetuximab	biological	2016	-	WO_2016_124702	PCT/EP2016/052408	n/a	n/a	n/a	n/a	
cetuximab	biological	2016	-	WO_2016_135041	PCT/EP2016/053475	n/a	n/a	n/a	n/a	
cetuximab	biological	2016	-	WO_2016_135066	PCT/EP2016/053607	n/a	n/a	n/a	n/a	
cetuximab	biological	2016	-	WO_2016_110226	PCT/CN2016/070024	n/a	n/a	n/a	n/a	

Supplemental File: Medicines under exclusivity situation funded by the Ministry of Health: analysis of the patent situation and public procurement. Gabriela Costa Chaves, et al. Fiocruz.

cyclophosphamide	synthetic	1966	US3732340	n/a	n/a	n/a	n/a	n/a	n/a	
cyclophosphamide	synthetic	1971	GB1235022	n/a	n/a	n/a	n/a	n/a	n/a	
cyclophosphamide	synthetic	1982	US4537883	n/a	n/a	n/a	n/a	n/a	n/a	
cyclophosphamide	synthetic	1998	-	WO199912942	EP1998005170	PI9814266-6	Granted	3	2	
cyclophosphamide	synthetic	2001	-	WO2001062300	US2001005709	PI0108930	n/a	n/a	n/a	
cyclophosphamide	synthetic	2001	-	WO 2001064217	EP2001002168	n/a	n/a	n/a	n/a	
cyclophosphamide	synthetic	2009	-	WO 2009118142	EP2009002111	PI 0909227- 7	n/a	n/a	n/a	
cyclophosphamide	synthetic	2009	-	WO 2010059969	US2009065381	PI 0916138-4	n/a	n/a	n/a	
cyclophosphamide	synthetic	2009	-	WO 2009137378	US2009042657	n/a	n/a	n/a	n/a	
cyclophosphamide	synthetic	2014	US 2015157652	WO2015089159	US2014069501	n/a	n/a	n/a	n/a	
cyclophosphamide	synthetic	2015	US 2017174780	WO2015130728	US2015017420	BR 11 2016 019866 2	n/a	n/a	n/a	
cladribine	synthetic	1969	AT274001	n/a	n/a	n/a	n/a	n/a	n/a	
cladribine	synthetic	1986	EP 173059	n/a	n/a	n/a	n/a	n/a	n/a	
cladribine	synthetic	2007	-	WO 2007103009	US2007004841	PI 0708446-3	Pending	2	n/a	
cladribine	synthetic	2007	-	WO 2007115286	US2007065911	PI 0710291-7	n/a	n/a	n/a	
cladribine	synthetic	2007	-	WO 2007135172	EP2007055013	PI 0710326-3	Dismissed	2	n/a	
cladribine	synthetic	2011	EP 2343074	n/a	n/a	n/a	n/a	n/a	n/a	
cladribine	synthetic	2011	-	WO 2011117267	EP2011054388	n/a	n/a	n/a	n/a	
daclatasvir	synthetic	2007	-	2008/021928	US2007075545	PI0716220-0	Pending	2	n/a	
daclatasvir	synthetic	2007	US8642025; US8900566; US9421192; US8329159; CA2660520	WO2008021927	PCT/US2007/075544	PI0716483	Pending	3	1	
daclatasvir	synthetic	2008	US8629171; CA2695729	WO2009020828	PCT/US2008/071734	PI0815142	Pending	2	n/a	
daclatasvir	synthetic	2008	-	2009/020825	US2008071696	PI0815611-5	Pending	3	2	
daclatasvir	synthetic	2010	-	2011/046811	US2010051898	BR 11 2012 008533	Pending	2	n/a	
daclatasvir	synthetic	2010	-	WO2011059887	US2010055565	BR 11 2012 011100 0	Pending	2	n/a	
daclatasvir	synthetic	2010	-	WO2011059850	US2010055045	BR 11 2012 011134 5	Pending	3	2	
daclatasvir	synthetic	2010	-	2011/072370	CA2010001935	BR 11 2012 014729	Pending	2	n/a	
daclatasvir	synthetic	2011	-	2012/018829	US2011046285	BR 11 2013 002922	Pending	2	n/a	
daclatasvir	synthetic	2013	-	2013/106520	US2013020954	BR 11 2014 017266 8	Pending	2	n/a	
danazol	synthetic	1962	BE580902	n/a	n/a	n/a	n/a	n/a	n/a	
danazol	synthetic	1977	US 4055562	n/a	n/a	n/a	n/a	n/a	n/a	
danazol	synthetic	2001	-	WO 2002038159	JP2001009764	n/a	n/a	n/a	n/a	
danazol	synthetic	2005	JP 2005263742	n/a	n/a	n/a	n/a	n/a	n/a	
danazol	synthetic	2010	US2010323991; US2010324005; US2012035147; US 2012077789	WO2010151530	US2010039458	PI 1010086-5	Pending	2	n/a	

Supplemental File: Medicines under exclusivity situation funded by the Ministry of Health: analysis of the patent situation and public procurement. Gabriela Costa Chaves, et al. Fiocruz.

danazol	synthetic	2010	US2010323991; US2010324005; US2012035147; US 2012077789	WO2010151531	US2010039461	PI 1010087-3	Pending	2	n/a	
danazol	synthetic	2010	-	WO 2011032907	EP2010063369	BR 11 2012 005938 6	n/a	n/a	n/a	
danazol	synthetic	2010	-	WO 2011033085	EP2010063735	BR 11 2012 006056 2	n/a	n/a	n/a	
danazol	synthetic	2010	-	WO 2011032916	EP2010063393	BR 11 2012 006067 8	Pending	2	n/a	
danazol	synthetic	2011	-	WO 2012027378	US2011048822	n/a	n/a	n/a	n/a	
darunavir	synthetic	1993	USRE42889; USRE43596; USRE43802; US5843946; US6248775; US6335460	WO9404492	PCT/US1993/007814	n/a	n/a	n/a	n/a	
darunavir	synthetic	1994	USRE42889; USRE43596; USRE43802; US5843946; US6248775; US6335460	WO9506030	PCT/US1994/009139	n/a	n/a	n/a	n/a	
darunavir	synthetic	1996	-	1996/28465	US1996002683	PI9607625-9	Extinct	3	1	
darunavir	synthetic	1996	US6037157; US6703403	WO9701349	PCT/US1996/011015	n/a	n/a	n/a	n/a	
darunavir	synthetic	1999	US7470506; US8597876; CA2336160; CA2872424	WO9967254	PCT/US1999/014120	n/a	n/a	n/a	n/a	
darunavir	synthetic	1999	US7470506; US8597876; CA2336160; CA2872424	WO9967417	PCT/US1999/014119	n/a	n/a	n/a	n/a	
darunavir	synthetic	2000	-	2001/25240	EP2000009917	PI0014602-1	Rejected	2	n/a	
darunavir	synthetic	2002	-	2002/081478	EP2002004012	PI0208796-0	Pending	2	n/a	
darunavir	synthetic	2002	-	2002/092595	EP2002005212	PI0209594-7	Dismissed	2	n/a	
darunavir	synthetic	2002	-	2003/022853	EP2002010062	PI0212341-0	Pending	2	n/a	
darunavir	synthetic	2002	-	2003/049746	EP2002014277	PI0215043-3	Dismissed	2	n/a	
darunavir	synthetic	2003	-	2004/014371	EP2003050359	PI0305717-8	Rejected	2	n/a	
darunavir	synthetic	2003	-	2003/097616	EP2003050173	PI0310089-8	Dismissed	2	n/a	
darunavir	synthetic	2003	US7700645; US8518987; CA2485834	WO03106461	PCT/EP2003/050176	PI0311176	Pending	2	n/a	
darunavir	synthetic	2003	US7700645; US8518987; CA2485834	WO03106461	PCT/EP2003/050176	BR 12 2015 012387 9	Pending	2	n/a	
darunavir	synthetic	2004	-	2004/099135	EP2004050753	PI0410158-8	Dismissed	2	n/a	
darunavir	synthetic	2004	-	2005/063770	EP2004053692	PI0417272-8	Pending	3	2	
darunavir	synthetic	2005	-	2005/095410	EP2005051452	PI0509514-0	Pending	3	2	
darunavir	synthetic	2005	-	2006/005720	EP2005053266	PI0513051-4	Dismissed	2	n/a	
darunavir	synthetic	2006	-	2006/089942	EP2006060246	PI0607827-3	Pending	2	n/a	
darunavir	synthetic	2012	-	2013/004816	EP2012063242	BR 11 2014 000195 2	Pending	2	n/a	

Supplemental File: Medicines under exclusivity situation funded by the Ministry of Health: analysis of the patent situation and public procurement. Gabriela Costa Chaves, et al. Fiocruz.

darunavir	synthetic	2012	-	2013/004818	EP2012063249	BR 11 2014 000290 8	Pending	2	n/a	
dasatinib	synthetic	2000	US6596746; US7125875; US7153856; CA2366932; CA2519898;	WO200062778	PCT/US2000/009753	PI0009721	Pending	3	1	
dasatinib	synthetic	2004	US6596746; US7125875; US7153856; CA2366932; CA2519898;	WO2004085388	PCT/US2004/008827	PI0408782	Pending	2	n/a	
dasatinib	synthetic	2005	US7491725; US8680103; CA2555291	WO2005077945	PCT/US2005/003728	PI0507476	Pending	2	n/a	
dasatinib	synthetic	2005	US7491725; US8680103; CA2555291	WO2006052810	PCT/US2005/040145	PI0515721	Dismissed	2	n/a	
deferasirox	synthetic	1997	US6465504; US6596750	WO199749395	EP1997003315	PI9709973	Granted	3	1	
deferasirox	synthetic	2003	-	2004/035026	EP2003011351	PI0315264-2	Pending	2	n/a	
deferasirox	synthetic	2005	-	2005/097062	EP2005003674	PI0509645-6	Dismissed	2	n/a	
deferasirox	synthetic	2006	-	WO2006084683	EP2006001118	PI0607058	Dismissed	n/a	n/a	
deferasirox	synthetic	2006	-	WO2006130532	US2006020677	PI0610873	Dismissed	n/a	n/a	
deferasirox	synthetic	2006	-	2007/045445	EP2006010020	PI0617715-8	Dismissed	2	n/a	
deferasirox	synthetic	2007	-	WO2008005624	US2007069319	PI0712020	Dismissed	n/a	n/a	
deferasirox	synthetic	2007	-	WO2008015021	EP2007006903	PI0715123	Dismissed	n/a	n/a	
deferasirox	synthetic	2014	US9283209	WO2014136079	IB2014059494	BR 11 2015 021254 9	Pending	2	n/a	
deferiprone	synthetic	1983	GB 2117766	n/a	n/a	n/a	n/a	n/a	n/a	
deferiprone	synthetic	1983	GB211 8176A	n/a	n/a	n/a	n/a	n/a	n/a	
deferiprone	synthetic	1985	GB211 8176B	n/a	n/a	n/a	n/a	n/a	n/a	
deferiprone	synthetic	1992	EP0501056	n/a	n/a	n/a	n/a	n/a	n/a	
deferiprone	synthetic	2001	US7049328	WO200202114	PCT/CA2001/000956	PI0112280	Rejected	2	n/a	
deferiprone	synthetic	2008	US8703156	WO2009129592	PCT/CA2008/000784	PI0822206	Pending	2	n/a	
degarelix	synthetic	1997	US5925730; CA2286190	WO9846634		PI9808523	Granted	3	1	
degarelix	synthetic	2008	US9415085; US9579359	WO2009101530		PI0908127	Pending	2	n/a	
degarelix	synthetic	2008	US9415085; US9579359	WO2009101530		PI0908129	Dismissed	2	n/a	
didanosine	synthetic	1986	US4861759; US5254539; US5616566	WO8701284	PCT/US1986/001622	n/a	n/a	n/a	n/a	
didanosine	synthetic	1990	US4861759	WO9014091	PCT/US1990/002686	n/a	n/a	n/a	n/a	
didanosine	synthetic	1991	US5880106	n/a	n/a	n/a	n/a	n/a	n/a	
didanosine	synthetic	1991	-	1991/18611	US1991003174	PI9106503-8	n/a	n/a	n/a	

Supplemental File: Medicines under exclusivity situation funded by the Ministry of Health: analysis of the patent situation and public procurement. Gabriela Costa Chaves, et al. Fiocruz.

didanosine	synthetic	1993	-	n/a	n/a	PP1100041-4	Expired	2	n/a	
didanosine	synthetic	1994	-	1994/22480	US1994003209	PI9406503-9	n/a	n/a	n/a	
didanosine	synthetic	1995	-	1995/33464	US1995006673	PI9507912-2	Rejected	2	n/a	
didanosine	synthetic	1995	-	1996/10399	CA1995000561	PI9509217-0	Rejected	2	n/a	
didanosine	synthetic	1998	-	99/32100	JP1998005708	PI9813691-7	n/a	n/a	n/a	
didanosine	synthetic	1998	CA2332922	WO9961002	PCT/US1998/016128	PI9815861	Granted	2	n/a	
didanosine	synthetic	1998	-	2000/03696	US1998016323	PI9815948-8	Rejected	2	n/a	
didanosine	synthetic	2004	-	2004/078993	US2004006103	PI0407959-0	Dismissed	2	n/a	
dolutegravir	synthetic	2005	US8129385; CA2606282	2006/116764	US2006016604	PI0610030	Pending	3	3	
dolutegravir	synthetic	2005	US8129385; CA2606282	2007/049675	JP2006321335	PI0617842	Dismissed	2	n/a	
dolutegravir	synthetic	2008	US9242986	2010/068253	US2009006422	PI0923217	Pending	3	2	
dolutegravir	synthetic	2011	-	2011/094150	US2011022219	BR 11 2012 018670 1	Pending	2	n/a	
dolutegravir	synthetic	2011	-	2012/018065	JP2011067832	BR 11 2013 002461 5	Pending	3	2	
enfuvirtide	synthetic	1986	US5112861	n/a	-	n/a	n/a	n/a	n/a	
enfuvirtide	synthetic	1994	US5464933; US6133418	WO9428920	PCT/US1994/005739	n/a	n/a	n/a	n/a	
enfuvirtide	synthetic	1995	US5464933; US6133418	WO9619495	PCT/US1995/016733	n/a	n/a	n/a	n/a	
enfuvirtide	synthetic	1996	US6475491	WO9640191	PCT/US1996/009499	PI9609152	Rejected	2	n/a	
enfuvirtide	synthetic	2000	-	2000/069911	US2000013563	PI0010750-6	Rejected	3	1	
enfuvirtide	synthetic	2000	-	2000/69902	US2000013651	PI0010757-3	Dismissed	3	1	
enfuvirtide	synthetic	2000	US6500867	WO0101984	PCT/FI2000/000593	PI0011867	n/a	n/a	n/a	
enfuvirtide	synthetic	2001	-	2002/056902	US2001048802	PI0116253-5	Dismissed	2	n/a	
enfuvirtide	synthetic	2003	-	2004/013164	EP2003007710	PI0312889-0	Pending	2	n/a	
enfuvirtide	synthetic	2003	-	2004/028473	US2003030538	PI0314711-8	n/a	n/a	n/a	
enfuvirtide	synthetic	2003	-	n/a	n/a	PI0400283-0	Dismissed	3	2	
enfuvirtide	synthetic	2006	-	2006/108594	EP2006003256	PI0609555-0	Dismissed	2	n/a	
entecavir	synthetic	1992	JP 1992282373	n/a	n/a	n/a	n/a	n/a	n/a	
entecavir	synthetic	1997	US5206244; EP481754	WO9809964	US1997015007	PP1100846	Expired	3	1	
entecavir	synthetic	2001	EP1566174; EP1145711	WO03030868	PCT/US2001/031530	PI0003158	n/a	n/a	n/a	
entecavir	synthetic	2001	EP1566174; EP1145711	WO03030868	PCT/US2001/031530	PI0117147	n/a	n/a	n/a	
entecavir	synthetic	2001	US6627224; US2001033864; EP1642582; EP1267880; CN102772413	WO0164221	PCT/US2001/002630	PI 0108435-6	Pending	2	n/a	
entecavir	synthetic	2003	EP 1492510	WO 2003086367	PCT/US2003/010371	PI 0309057-4	Dismissed	2	n/a	
entecavir	synthetic	2003	-	WO/2004/052310	US2003039554	PI 0317255-4	Pending	3	2	

Supplemental File: Medicines under exclusivity situation funded by the Ministry of Health: analysis of the patent situation and public procurement. Gabriela Costa Chaves, et al. Fiocruz.

entecavir	synthetic	2005	US7511139; US2005272932; EP1751158; JP2008501711	WO 2005118585	PCT/US2005/019633	PI 0510743-1	Pending	3	2	
entecavir	synthetic	2006	-	WO 2007030657	PCT/US2006/034923	n/a	n/a	n/a	n/a	
entecavir	synthetic	2007	US 2007060599	WO/2007/133820	PCT/US2007/060599	n/a	n/a	n/a	n/a	
enzalutamide	synthetic	2005	US7709517; US8183274; US9126941; CA2608436	WO2006124118		PI0610359	Pending	3	1	
enzalutamide	synthetic	2005	US7709517; US8183274; US9126941; CA2608436	WO2006124118		PI0709682	Pending	3	3	
eribulin	synthetic	1999	US6214865; US6469182; US7470720; US8097648; CA2335300	WO9965894	PCT/US1999/013677	PI9911326	Granted	1	1	
eribulin	synthetic	1999	CA 2335300	WO9965894	PCT/US1999/013677	PI9917807-9	Rejected	2	n/a	
eribulin	synthetic	2003	CA 2335300	WO2004034990	PCT/US2003/032711	n/a	n/a	n/a	n/a	
eribulin	synthetic	2006	CA 2335300	WO2007061874	PCT/US2006/044731	n/a	n/a	n/a	n/a	
eribulin	synthetic	2011	-	2011/094339	US2011022611	BR 11 2012 018232 3	Pending	3	2	
eribulin	synthetic	2013	-	2014/087230	IB2013002911	BR 11 2015 012731 2	Pending	2	n/a	
eribulin	synthetic	2014	-	2014/208774	JP2014067723	BR 11 2015 029386 7	Pending	2	n/a	
eribulin	synthetic	2014	-	2015/066729	US2014063960	BR 11 2016 009452 2	Pending	3	2	
eribulin	synthetic	2014	-	2015/085193	US2014068834	BR 11 2016 012237 2	Pending	2	n/a	
eribulin	synthetic	2015	-	2015/134399	US2015018335	BR 11 2016 019968 5	Pending	2	n/a	
eribulin	synthetic	2015	-	2015/183961	US2015032684	BR 11 2016 026545 9	Pending	2	n/a	
eribulin	synthetic	2016	-	2016/141209	US2016020734	BR 11 2017 018872 4	Pending	2	n/a	
eribulin	synthetic	2016	-	2016/141209	US2016020734	BR 11 2017 018913 5	Pending	2	n/a	
eribulin	synthetic	2016	-	2016/141209	US2016020734	BR 11 2017 018927 5	Pending	2	n/a	
erlotinib	synthetic	1995	US5747498; USRE41065	WO9630347	PCT/IB1995/000436	PI9601200	Granted	3	3	
erlotinib	synthetic	2000	CA2389333; CA2632556; US6900221; US7087613	WO0134574	PCT/US2000/031009	PI0015544	Rejected	3	2	
erlotinib	synthetic	2000	CA2389333; CA2632556	WO0134574	PCT/US2000/031009	PI0017569-2	Rejected	2	n/a	
erlotinib	synthetic	2004	CA2514977	WO2004072049	PCT/EP2004/001244	PI0407520	Pending	2	n/a	
erlotinib	synthetic	2005	-	2005/117887	EP2005005735	PI 0511760-7	Dismissed	3	2	
erlotinib	synthetic	2005	-	2005/117915	EP2005005638	PI 0511780-1	Dismissed	3	2	
erlotinib	synthetic	2005	-	2005/117877	EP2005005639	PI 0511800-0	Dismissed	3	2	
erlotinib	synthetic	2011	-	2012/049192	EP2011067757	BR 11 2013 009143 6	Pending	2	n/a	
erlotinib	synthetic	2013	-	2013/182537	EP2013061430	BR 11 2014 028659 0	Pending	2	n/a	

Supplemental File: Medicines under exclusivity situation funded by the Ministry of Health: analysis of the patent situation and public procurement. Gabriela Costa Chaves, et al. Fiocruz.

etanercept	biological	1990	US 5395760	-	-	-	n/a	n/a	n/a	
etanercept	biological	1993	-	WO/1994/010990	PCT/GB1993/002331	-	n/a	n/a	n/a	
etanercept	biological	1999	-	WO200018409	SE1999001671	PI9913926	Dismissed	n/a	n/a	
etanercept	biological	2000	-	WO_2000_073481	PCT/US2000/014586	n/a	n/a	n/a	n/a	
etanercept	biological	2000	-	WO_2001_011034	PCT/US2000/021693	n/a	n/a	n/a	n/a	
etanercept	biological	2000	CA 2366785	WO2000062790	PCT/US2000/010565	n/a	n/a	n/a	n/a	
etanercept	biological	2000	-	WO2001000229	US2000016292	n/a	n/a	n/a	n/a	
etanercept	biological	2001	CA 2366785	WO200162272	PCT/US2001/006037	n/a	n/a	n/a	n/a	
etanercept	biological	2001	US 6531128	WO2001058469	US2001000686	n/a	n/a	n/a	n/a	
etanercept	biological	2001	-	WO2001058473	US2001004048	PI 0108193-4	n/a	n/a	n/a	
etanercept	biological	2001	CA 2366785	WO2001062272	PCT/US2001/006037	n/a	n/a	n/a	n/a	
etanercept	biological	2002	-	WO2003045400	IB2002004367	PI 0214810-2	n/a	n/a	n/a	
etanercept	biological	2003	CA 2476934	WO2003072060	PCT/US2003/006222	n/a	n/a	n/a	n/a	
etanercept	biological	2003	-	WO2004037205	US2003033973	PI0315597	Dismissed	n/a	n/a	
etanercept	biological	2003	-	WO2004060920	US2003041691	PI0317896	Dismissed	n/a	n/a	
etanercept	biological	2004	-	WO2004067006	IB2004000616	n/a	n/a	n/a	n/a	
etanercept	biological	2004	US 2004235047	WO2005018535	PCT/US2004/015864	PI 0410467-6	n/a	n/a	n/a	
etanercept	biological	2004	-	WO_2005_012353	PCT/US2004/024738	PI 0413197-5	Dismissed	n/a	n/a	
etanercept	biological	2005	-	WO2005117966	EP2005052436	PI0511683	Dismissed	n/a	n/a	
etanercept	biological	2006	-	WO_2007_022070	PCT/US2006/031609	n/a	n/a	n/a	n/a	
etanercept	biological	2007	-	WO2008005315	US2007015095	PI0713802	n/a	n/a	n/a	
etanercept	biological	2008	-	WO_2009_086320	PCT/US2008/088053	PI 0821604-5	Pending	3	3	
etanercept	biological	2010	-	WO_2011_053541	PCT/US2010/053903	BR 11 2012 009886 1	Dismissed	n/a	n/a	
etanercept	biological	2010	-	WO_2010_118360	PCT/US2010/030589	n/a	n/a	n/a	n/a	
etanercept	biological	2010	-	WO_2011_053612	PCT/US2010/054183	n/a	n/a	n/a	n/a	
etanercept	biological	2011	-	WO_2012_046255	PCT/IN2011/000703	BR 11 2013 008459 6	Pending	3	2	
etanercept	biological	2012	-	WO_2013_025079	PCT/KR2012/006564	BR 11 2014 003670 5	Pending	3	2	
etanercept	biological	2012	-	WO_2012_115903	PCT/US2012/025809	n/a	n/a	n/a	n/a	
etanercept	biological	2012	-	WO_2012_115904	PCT/US2012/025812	n/a	n/a	n/a	n/a	
etanercept	biological	2013	-	WO_2014_121481	PCT/CN2013/071497	n/a	n/a	n/a	n/a	
etanercept	biological	2013	-	WO_2013_123034	PCT/US2013/025917	n/a	n/a	n/a	n/a	
etanercept	biological	2014	-	WO_2015_080513	PCT/KR2014/011540	BR 11 2016 011224 5	Pending	2	n/a	
etanercept	biological	2014	-	WO_2014_136114	PCT/IL2014/050228	BR 11 2015 021708 7	Pending	3	3	
etanercept	biological	2014	-	WO_2014_136113	PCT/IL2014/050227	n/a	n/a	n/a	n/a	
etanercept	biological	2014	-	WO_2014_144911	PCT/US2014/029511	n/a	n/a	n/a	n/a	
etanercept	biological	2015	-	WO_2015_114150	PCT/EP2015/052098	BR 11 2016 017698 7	Pending	3	1	
etanercept	biological	2015	-	WO_2015_171965	PCT/US2015/029795	BR 11 2016 025866 5	Pending	2	n/a	
etanercept	biological	2015	-	WO_2016_009036	PCT/EP2015/066385	BR 11 2017 000955 2	Pending	2	n/a	
etanercept	biological	2015	-	WO_2016_069574	PCT/US2015/057533	BR 11 2017 008525 9	Pending	3	1	
etanercept	biological	2016	-	WO_2016_112870_A1	PCT/CN2016/071184	n/a	n/a	n/a	n/a	
etoposide	synthetic	1965	US3524844	n/a	n/a	n/a	n/a	n/a	n/a	
etoposide	synthetic	1968	CH 514578	n/a	n/a	n/a	n/a	n/a	n/a	
etoposide	synthetic	1983	JP 58219196	n/a	n/a	n/a	n/a	n/a	n/a	

Supplemental File: Medicines under exclusivity situation funded by the Ministry of Health: analysis of the patent situation and public procurement. Gabriela Costa Chaves, et al. Fiocruz.

etoposide	synthetic	1984	EP 111058	n/a	n/a	n/a	n/a	n/a	n/a	
etoposide	synthetic	1987	USRE35524	n/a	n/a	n/a	n/a	n/a	n/a	
etoposide	synthetic	1987	US5041424	n/a	n/a	n/a	n/a	n/a	n/a	
etoposide	synthetic	1991	-	WO 1992010198	AU1991000563	n/a	n/a	n/a	n/a	
etoposide	synthetic	1997	-	98/03516	IB1997000800	PI 9710381-0	n/a	n/a	n/a	
etoposide	synthetic	1997	-	98/07697	IB1997000924	PI 9711223-2	n/a	n/a	n/a	
etoposide	synthetic	1997	-	98/30566	IB1997001582	PI 9714266-2	n/a	n/a	n/a	
etoposide	synthetic	1998	-	98/34918	IB1998000064	PI 9807678-7	n/a	n/a	n/a	
etoposide	synthetic	1998	-	98/33768	IB1998000023	PI 9807815-1	n/a	n/a	n/a	
etoposide	synthetic	1999	-	99/52889	IB1999000505	PI 9909562-9	n/a	n/a	n/a	
etoposide	synthetic	1999	-	00/09485	IB1999001388	PI 9912909-4	n/a	n/a	n/a	
etoposide	synthetic	1999	-	00/09492	IB1999001392	PI 9912944-2	n/a	n/a	n/a	
etoposide	synthetic	2000	-	00/73294	IB2000000646	PI 0011538-0	n/a	n/a	n/a	
etoposide	synthetic	2000	-	00/73295	IB2000000647	PI 0011539-8	n/a	n/a	n/a	
etoposide	synthetic	2001	-	WO 2001064198	EP2001002167	n/a	n/a	n/a	n/a	
etoposide	synthetic	2005	-	WO 2005070465	US2005001149	n/a	n/a	n/a	n/a	
etoposide	synthetic	2014	-	WO 2014168975	US2014033378	BR 11 2015 025711 9	n/a	n/a	n/a	
etravirine	synthetic	1999	-	1999/50250	EP1999002043	PI9909191-7	Pending	2	n/a	
etravirine	synthetic	1999	US6887817; US7037917; US8003789; CA2350801	WO0027825		PI9915552	Granted	3	3	
etravirine	synthetic	1999	US7887845; CA2384188	WO0027828		PI9915176	Dismissed	2	n/a	
etravirine	synthetic	2000	US7887845; CA2384188	WO0122938		PI0014271	Pending	2	n/a	
etravirine	synthetic	2003	-	2004/050058	EP2003050890	PI0316532-9	Pending	2	n/a	
etravirine	synthetic	2006	-	2006/079656	EP2006050490	PI0607214-3	Pending	2	n/a	
etravirine	synthetic	2006	-	2006/094930	EP2006060407	PI0609291-8	Pending	3	3	
etravirine	synthetic	2006	CA2651665	WO2007141308		PI0712346	Pending	2	n/a	
etravirine	synthetic	2010	-	2010/112411	EP2010053970	PI 1012666-0	Pending	2	n/a	
exemestane	synthetic	1985	US4808616; US4904650	n/a	n/a	PP1100240	Expired	3	3	
exemestane	synthetic	2001	CA2409059	WO0187266	EP2001004643	PI0110841	Rejected	2	n/a	
exemestane	synthetic	2005	-	2006/048749	IB2005003307	PI0515735-8	Dismissed	3	2	
fosamprenavir	synthetic	1992	-	n/a	n/a	PP1100824-5	Expired	3	1	
fosamprenavir	synthetic	1996	-	1996/33184	US1996005475	PI9608032-9	Rejected	2	n/a	
fosamprenavir	synthetic	1996	-	1997/20554	US1996019447	PI9611861-0	Rejected	2	n/a	
fosamprenavir	synthetic	1997	-	1997/35587	EP1997001438	PI9708238-4	Granted	2	n/a	
fosamprenavir	synthetic	1997	-	1997/49411	EP1997003247	PI9709939-2	Dismissed	n/a	n/a	
fosamprenavir	synthetic	1998	US6436989; CA2231700	WO9933815		PI9814480	Rejected	3	1	
fosamprenavir	synthetic	1998	-	1999/33793	US1998027424	PI9814484-7	Dismissed	2	n/a	

Supplemental File: Medicines under exclusivity situation funded by the Ministry of Health: analysis of the patent situation and public procurement. Gabriela Costa Chaves, et al. Fiocruz.

fosamprenavir	synthetic	1999	-	1999/48885	GB1999000852	PI9908970-0	Rejected	3	2
fosamprenavir	synthetic	1999	-	1999/66936	US1999014329	PI9911457-7	Dismissed	2	n/a
fosamprenavir	synthetic	1999	US6514953; CA2337857	WO0004033		PI9912156	Granted	2	n/a
gefitinib	synthetic	1992	US5457105; US5616582	n/a	n/a	n/a	n/a	n/a	n/a
gefitinib	synthetic	1996	US5770599	WO9633980	PCT/GB1996/000961	PI9608082	Pending	3	1
gefitinib	synthetic	2002	-	WO03072139	PCT/GB2003/000803	PI0307786	Pending	2	n/a
gefitinib	synthetic	2002	-	WO03072108	PCT/GB2003/000794	PI0308023	Pending	3	2
gefitinib	synthetic	2003	-	WO2004024703		PI0314238	Pending	3	2
glatiramer	synthetic	1995	US5981589; US6054430; US6342476; US6362161; US6620847; US6939539; US7199098	95/31990	US1995006551	PI9507758	Rejected	2	n/a
glatiramer	synthetic	1998	-	98/30227	US1998000375	PI9807076	Granted	2	n/a
glatiramer	synthetic	2005	-	2005/112972	US2005016344	PI0510738	Pending	2	n/a
glatiramer	synthetic	2005	-	2006/029393	US2005032395	PI0515033-7	Pending	3	2
glatiramer	synthetic	2006	-	2006/083608	US2006002351	PI0606301	Dismissed	n/a	n/a
glatiramer	synthetic	2008	CA 2702437	WO2009070298	PCT/US2008/013146	PI0819001	Dismissed	2	n/a
glatiramer	synthetic	2010	-	2011/008274	US2010001972	BR 11 2012 000878 1	Pending	2	n/a
glatiramer	synthetic	2010	US8232250; US8399413; US8969302; US9155776; US9402874; CA2760802	WO2011022063	PCT/US2010/002283	BR 11 2012 003730 7	Pending	2	n/a
glatiramer	synthetic	2011	EP2563804	WO2011139752	US2011034102	BR 11 2012 027753	Pending	3	2
glatiramer	synthetic	2011	-	2012/051106	US2011055588	BR 11 2013 008573 8	Pending	2	n/a
glatiramer	synthetic	2012	-	2013/016684	US2012048684	BR 11 2014 002095 7	Pending	2	n/a
glatiramer	synthetic	2013	-	2014/100643	US2013077041	BR 11 2015 014092 0	Pending	2	n/a
glatiramer	synthetic	2013	-	2014/100639	US2013077034	BR 11 2015 014095 5	Pending	2	n/a
glatiramer	synthetic	2015	-	2016/122722	US2015051203	BR 11 2016 023736 6	Pending	2	n/a
golimumab	biological	1992	CA2419205	WO9216553	PCT/US1992/002190	n/a	n/a	n/a	n/a
golimumab	biological	2001	CA2419205	WO0212502	PCT/US2001/024785	PI0113110	Pending	3	2
golimumab	biological	2001	CA2419205	WO0212502	PCT/US2001/024785	BR 12 2013 012507 8	Pending	3	1
golimumab	biological	2005	CA2419205	WO2006065975	PCT/US2005/045388	n/a	n/a	n/a	n/a
gosserelein	synthetic	1976	US4100274	n/a	n/a	n/a	n/a	n/a	n/a
gosserelein	synthetic	1981	US4767628	n/a	n/a	n/a	n/a	n/a	n/a
gosserelein	synthetic	1981	US5366734	n/a	n/a	n/a	n/a	n/a	n/a
gosserelein	synthetic	1997	-	WO199800157	US1997010816	PI9710130	Rejected	2	n/a
gosserelein	synthetic	1997	-	WO199800152	US1997010815	PI9710131	Rejected	2	n/a

Supplemental File: Medicines under exclusivity situation funded by the Ministry of Health: analysis of the patent situation and public procurement. Gabriela Costa Chaves, et al. Fiocruz.

goserelin	synthetic	2001	US7118552; US7220247; US7500964	WO200160435	GB2001000590	PI0108460	n/a	n/a	n/a	
hydroxyurea	synthetic	1955	US 2705727	n/a	n/a	n/a	n/a	n/a	n/a	
hydroxyurea	synthetic	1962	DE 1135890	n/a	n/a	n/a	n/a	n/a	n/a	
hydroxyurea	synthetic	1963	US3968249	n/a	n/a	n/a	n/a	n/a	n/a	
hydroxyurea	synthetic	1991	EP0420193	n/a	n/a	n/a	n/a	n/a	n/a	
hydroxyurea	synthetic	1992	-	WO 1993008801	PCT/US1992/009126	n/a	n/a	n/a	n/a	
hydroxyurea	synthetic	1995	US5506261	WO 199530671	US1995/005254	n/a	n/a	n/a	n/a	
iloprost	synthetic	1985	DE 3427797	WO 198600808	DE1985000245	n/a	n/a	n/a	n/a	
iloprost	synthetic	1987	-	WO 1988001867	DE1987000401	n/a	n/a	n/a	n/a	
iloprost	synthetic	1992	-	WO 1992013537	DE1992000091	n/a	n/a	n/a	n/a	
iloprost	synthetic	1992	-	WO 1992014438	DE1992000100	n/a	n/a	n/a	n/a	
iloprost	synthetic	1993	-	WO 1994003175	DE1993000722	n/a	n/a	n/a	n/a	
iloprost	synthetic	1996	-	WO 1997006806	EP1996003481	PI 9609932-1	n/a	n/a	n/a	
iloprost	synthetic	2003	-	WO 2003103681	EP2003005990	n/a	n/a	n/a	n/a	
iloprost	synthetic	2004	-	WO 2005009446	US2004023004	n/a	n/a	n/a	n/a	
iloprost	synthetic	2004	-	WO 2005030187	US2004031149	n/a	n/a	n/a	n/a	
iloprost	synthetic	2005	-	WO 2006014930	US2005026449	PI 0513866-3	Dismissed	2	n/a	
iloprost	synthetic	2008	EP 2065054	WO 2009068190	EP2008009639	n/a	n/a	n/a	n/a	
imiglucerase	biological	1989	US5236838; US5549892; US6451600; US2005019861; US2005026249	WO1990007573	PCT/US1989/005801	n/a	n/a	n/a	n/a	
imiglucerase	biological	1992	-	WO1992013067	US1992000431	n/a	n/a	n/a	n/a	
imiglucerase	biological	1992	-	WO1993013196	US1992011188	n/a	n/a	n/a	n/a	
Anti-hepatitis B immunoglobulin	biological	2000	-	WO 2000059539	SE2000000619	n/a	n/a	n/a	n/a	
l-asparaginase	biological	1969	DE1904850	n/a	n/a	n/a	n/a	n/a	n/a	
l-asparaginase	biological	1971	JP 46042954	n/a	n/a	n/a	n/a	n/a	n/a	
l-asparaginase	biological	1987	EP0211639	n/a	n/a	n/a	n/a	n/a	n/a	
l-asparaginase	biological	2001	-	WO_2001_055301	PCT/US2001/001239	n/a	n/a	n/a	n/a	
l-asparaginase	biological	2007	-	WO_2007_083100	PCT/GB2007/000124	n/a	n/a	n/a	n/a	
l-asparaginase	biological	2007	-	WO_2008_011234	PCT/US2007/070706	n/a	n/a	n/a	n/a	
l-asparaginase	biological	2007	-	WO_2012_049662	PCT/US2007/070706	n/a	n/a	n/a	n/a	
l-asparaginase	biological	2007	-	WO_2007_083100	PCT/GB2007/000124	n/a	n/a	n/a	n/a	
l-asparaginase	biological	2007	-	WO_2007_132461	PCT/IL2007/000585	n/a	n/a	n/a	n/a	
l-asparaginase	biological	2008	-	WO_2008_126784	PCT/JP2008/056759	n/a	n/a	n/a	n/a	
l-asparaginase	biological	2009	-	WO_2009_098263	PCT/EP2009/051332	n/a	n/a	n/a	n/a	
l-asparaginase	biological	2010	-	WO2011003633	PCT/EP2010/054156	n/a	n/a	n/a	n/a	

Supplemental File: Medicines under exclusivity situation funded by the Ministry of Health: analysis of the patent situation and public procurement. Gabriela Costa Chaves, et al. Fiocruz.

l-asparaginase	biological	2010	US 20120100121	WO2011003886	PCT/EP2010/059599	BR 11 2012 000367 4	Pending	3	3	
l-asparaginase	biological	2011	CN 102138909	n/a	n/a	n/a	n/a	n/a	n/a	
l-asparaginase	biological	2011	-	WO_2011_125015	PCT/IB2011/051433	n/a	n/a	n/a	n/a	
l-asparaginase	biological	2011	-	WO_2012_075173	PCT/US2011/062690	n/a	n/a	n/a	n/a	
l-asparaginase	biological	2012	-	WO_2013_056657	PCT/CN2012/083140	n/a	n/a	n/a	n/a	
l-asparaginase	biological	2012	-	WO_2013_055699	PCT/US2012/059379	n/a	n/a	n/a	n/a	
l-asparaginase	biological	2013	-	WO_2013_148325	PCT/US2013/032180	n/a	n/a	n/a	n/a	
l-asparaginase	biological	2014	-	WO 2015033344	IL2014050795	n/a	n/a	n/a	n/a	
l-asparaginase	biological	2014	-	WO_2015_038639	PCT/US2014/054977	n/a	n/a	n/a	n/a	
l-asparaginase	biological	2015	-	WO_2016_106941	PCT/CN2015/072167	n/a	n/a	n/a	n/a	
lanreotide	synthetic	1995	US 5595760	WO9607397	PCT/IB1995/000778	PI9508687	Expired	2	n/a	
lanreotide	synthetic	1995	US 5595760	WO9607398	PCT/IB1995/000793	PI9508688	Dismissed	2	n/a	
lanreotide	synthetic	1995	US 5595760	WO9607398	PCT/IB1995/000793	PI9510791-6	Dismissed	3	2	
lanreotide	synthetic	1995	US 5595760	WO9607440	PCT/IB1995/000779	n/a	n/a	n/a	n/a	
lanreotide	synthetic	1997	-	1997/039738	IE1997000030	PI9708818	Rejected	2	n/a	
lanreotide	synthetic	1998	-	98/47489	FR1998000773	PI9808933	Dismissed	n/a	n/a	
lanreotide	synthetic	1999	-	00/06185	US1999017294	PI9912609	Dismissed	n/a	n/a	
lapatinib	synthetic	1997	US6391874; US6828320	WO9802434	PCT/EP1997/003672	n/a	n/a	n/a	n/a	
lapatinib	synthetic	1999	US6713485; US6727256; US8513262; CA2317589	WO9935146	PCT/EP1999/000048	PI9906904	Granted	3	1	
lapatinib	synthetic	2001	US7157466; CA2413134	WO0202552	PCT/US2001/020706	PI0111947	Rejected	3	1	
lapatinib	synthetic	2006	US8821927; CA2606207	WO2006113649	PCT/US2006/014447	PI0609962	Pending	2	n/a	
lomustine	synthetic	2004	-	WO 2005025620	US2004026394	n/a	n/a	n/a	n/a	
lomustine	synthetic	2014	-	WO 2015021929	CN2014084324	n/a	n/a	n/a	n/a	
lomustine	synthetic	2014	-	WO 2015086473	EP2014076786	n/a	n/a	n/a	n/a	
lopinavir/ritonavir	synthetic	1992	US5541206; US5635523; US5648497; US5674882; US5846987; US5886036	WO9217176	PCT/US1992/002120	n/a	n/a	n/a	n/a	
lopinavir/ritonavir	synthetic	1993	US5541206; US5635523; US5648497; US5674882; US5846987; US5886036	WO9323361	PCT/US1993/004403	n/a	n/a	n/a	n/a	

Supplemental File: Medicines under exclusivity situation funded by the Ministry of Health: analysis of the patent situation and public procurement. Gabriela Costa Chaves, et al. Fiocruz.

lopinavir/ritonavir	synthetic	1993	US5541206; US5635523; US5648497; US5674882; US5846987; US5886036	WO9414436	PCT/US1993/012326	n/a	n/a	n/a	n/a	
lopinavir/ritonavir	synthetic	1994	US5948436	WO9507696	PCT/US1994/009788	n/a	n/a	n/a	n/a	
lopinavir/ritonavir	synthetic	1995	US5484801	WO9520384	PCT/US1995/000232	n/a	n/a	n/a	n/a	
lopinavir/ritonavir	synthetic	1996	US6284767; US5914332	n/a	n/a	PP1100397	Granted	3	3	
lopinavir/ritonavir	synthetic	1996	US6284767; US5914332	n/a	n/a	PP1101190-4	Rejected	n/a	n/a	
lopinavir/ritonavir	synthetic	1996	US6284767	WO9721683	PCT/US1996/019394	n/a	n/a	n/a	n/a	
lopinavir/ritonavir	synthetic	1996	US6284767	WO9721685	PCT/US1996/020440	n/a	n/a	n/a	n/a	
lopinavir/ritonavir	synthetic	1996	US6037157; US6703403	WO9701349	PCT/US1996/011015	n/a	n/a	n/a	n/a	
lopinavir/ritonavir	synthetic	1996	US6232333; US6458818; US6521651	n/a	n/a	n/a	n/a	n/a	n/a	
lopinavir/ritonavir	synthetic	1997	US5541206; US5635523; US5648497; US5674882; US5846987; US5886036	n/a	n/a	PP1100661	Granted	3	1	
lopinavir/ritonavir	synthetic	1997	-	1998/22106	US1997020794	PI9714310-3	Granted	2	n/a	
lopinavir/ritonavir	synthetic	1998	US7148359	n/a	n/a	n/a	n/a	n/a	n/a	
lopinavir/ritonavir	synthetic	1999	US7364752	n/a	n/a	n/a	n/a	n/a	n/a	
lopinavir/ritonavir	synthetic	1999	US7141593; US7432294	n/a	n/a	n/a	n/a	n/a	n/a	
lopinavir/ritonavir	synthetic	1999	CA2337846; CA2510949	WO0004016		PI9912010	Rejected	2	n/a	
lopinavir/ritonavir	synthetic	2000	CA2390092	WO0134118	PCT/US2000/030910	n/a	n/a	n/a	n/a	
lopinavir/ritonavir	synthetic	2000	US6911214; US8501219	n/a	n/a	n/a	n/a	n/a	n/a	
lopinavir/ritonavir	synthetic	2000	-	2001/52821	US2000032771	PI0011864-8	Rejected	2	n/a	
lopinavir/ritonavir	synthetic	2001	US8470347	WO0191727	PCT/EP2001/006116	n/a	n/a	n/a	n/a	
lopinavir/ritonavir	synthetic	2001	-	2002/18349	US2001026898	PI0108146-2	Pending	3	3	
lopinavir/ritonavir	synthetic	2001	-	02/20057	US2001027415	PI0108433-0	Dismissed	2	n/a	
lopinavir/ritonavir	synthetic	2001	-	2001/74787	US2001009112	PI0109433-5	Rejected	2	n/a	
lopinavir/ritonavir	synthetic	2003	-	2004/032903	EP2003011205	PI0314984-6	Pending	2	n/a	
lopinavir/ritonavir	synthetic	2004	CA2536638	WO2005039551		PI0413882	Rejected	2	n/a	
lopinavir/ritonavir	synthetic	2005	-	2006/014282	US2005023047	PI0512970-2	Pending	3	3	
lopinavir/ritonavir	synthetic	2005	US8025899; US8268349; US8309613; US8377952; US8399015; US8691878; CA2598827	WO2006091529	PCT/US2006/005944	PI0609173	Rejected	2	n/a	
lopinavir/ritonavir	synthetic	2006	US8025899; CA2598827	WO2006091529	PCT/US2006/005944	BR122012031169	Pending	2	n/a	

Supplemental File: Medicines under exclusivity situation funded by the Ministry of Health: analysis of the patent situation and public procurement. Gabriela Costa Chaves, et al. Fiocruz.

lopinavir/ritonavir	synthetic	2007	-	2008/009689	EP2007057392	PI0715582-4	Pending	2	n/a	
maraviroc	synthetic	1999	US6586430; CA2350073	WO0038680		PI9905977	Dismissed	n/a	n/a	
maraviroc	synthetic	1999	US6586430; CA2350073	WO0038680		PI9916585	Rejected	3	1	
maraviroc	synthetic	1999	US6586430; CA2350073	WO0039091		PI9916680	Rejected	3	1	
maraviroc	synthetic	1999	US6586430; CA2350073	WO0039125		PI9917007	Granted	3	1	
maraviroc	synthetic	2000	US6667314; US7368460; US7576097; CA2408909	WO0190106		PI0110955	Granted	3	3	
maraviroc	synthetic	2002	-	2002/099383	US2002018078	PI0210157-2	Dismissed	2	n/a	
maraviroc	synthetic	2003	-	2003/084954	IB2003001220	PI0309118-0	Dismissed	3	1	
maraviroc	synthetic	2007	-	2007/144720	IB2007001508	PI0712843-6	Dismissed	2	n/a	
melphalan	synthetic	1986	-	WO 198704154	PCT/AU1986/000392	n/a	n/a	n/a	n/a	
melphalan	synthetic	2005	-	WO 2006056449	PCT/EP2005/012590	n/a	n/a	n/a	n/a	
melphalan	synthetic	2007	-	WO 2007082742	PCT/EP2007/000408	PI0706541-8	Dismissed	n/a	n/a	
melphalan	synthetic	2007	-	WO 2007101235	PCT/US2007/062936	n/a	n/a	n/a	n/a	
melphalan	synthetic	2009	US8410077; US9200088; CA2702603	WO 2009134347	US2009002572	PI0905080	n/a	n/a	n/a	
melphalan	synthetic	2009	-	WO 2010008726	PCT/US2009/047449	PI0914789-6	Dismissed	n/a	n/a	
melphalan	synthetic	2009	-	WO 2010061907	PCT/JP2009/070001	n/a	n/a	n/a	n/a	
melphalan	synthetic	2009	-	WO 2010065742	PCT/US2009/066588	n/a	n/a	n/a	n/a	
melphalan	synthetic	2012	-	WO 2012146625	EP2012057577	BR 11 2013 027584 7	Pending	2	n/a	
melphalan	synthetic	2012	US 2014120157; EP 2711000	n/a	n/a	BR 10 2013 004109	Pending	2	n/a	
melphalan	synthetic	2013	9493582	WO2013130666	PCT/US2013/028094	n/a	n/a	n/a	n/a	
melphalan	synthetic	2013	-	WO 2014065751	SE2013051246	n/a	n/a	n/a	n/a	
miglustate	synthetic	1994	US5472969	WO9426714	PCT/US1994/004974	n/a	n/a	n/a	n/a	
miglustate	synthetic	1998	US5525616	WO9830219	PCT/US1998/000031	n/a	n/a	n/a	n/a	
miglustate	synthetic	1998	-	WO9929321	US1998026241	PI9813508	Dismissed	n/a	n/a	
miglustate	synthetic	2000	CA 2368814	WO0062780	PCT/GB2000/001563	PI0009868	Rejected	3	1	
miglustate	synthetic	2011	-	WO 2012001641	PCT/IB2011/052864	n/a	n/a	n/a	n/a	
mitomycin	synthetic	1991	-	WO 1992010198	AU1991000563	n/a	n/a	n/a	n/a	
mitomycin	synthetic	2004	-	WO 2005102280	US2004014890	n/a	n/a	n/a	n/a	
mitomycin	synthetic	2006	-	WO 2007019845	DE2006001453	PI 0614835-2	n/a	n/a	n/a	
mitomycin	synthetic	2007	US7806265; US8186511; US9205075; US9539241; US9649428	WO2008008802	PCT/US2007/073195	n/a	n/a	n/a	n/a	

Supplemental File: Medicines under exclusivity situation funded by the Ministry of Health: analysis of the patent situation and public procurement. Gabriela Costa Chaves, et al. Fiocruz.

mitomycin	synthetic	2009	-	WO 2009100716	DE2009000196	PI 0906611-0	n/a	n/a	n/a	
mitomycin	synthetic	2014	US 2014057865	WO/2016/048376	PCT/US2014/057865	n/a	n/a	n/a	n/a	
mitomycin	synthetic	2014	US 2014221961	WO2014124265	US2014015312	n/a	n/a	n/a	n/a	
mitomycin	synthetic	2014	CN 104352498	n/a	n/a	n/a	n/a	n/a	n/a	
mitomycin	synthetic	2014	CN 104473866	n/a	n/a	n/a	n/a	n/a	n/a	
mitomycin	synthetic	2014	-	WO 2015059023	EP2014072201	n/a	n/a	n/a	n/a	
mitoxantrone	synthetic	1977	US4820738	n/a	n/a	n/a	n/a	n/a	n/a	
mitoxantrone	synthetic	1978	US4138415; US4197249	n/a	n/a	n/a	n/a	n/a	n/a	
mitoxantrone	synthetic	1978	US4278689	n/a	n/a	n/a	n/a	n/a	n/a	
mitoxantrone	synthetic	1978	US 895082	n/a	n/a	n/a	n/a	n/a	n/a	
mitoxantrone	synthetic	1980	US4197249	n/a	n/a	n/a	n/a	n/a	n/a	
mitoxantrone	synthetic	1985	US4617319	n/a	n/a	n/a	n/a	n/a	n/a	
mitoxantrone	synthetic	1989	US 4820738	n/a	n/a	n/a	n/a	n/a	n/a	
mitoxantrone	synthetic	1994	EP 0616813	n/a	n/a	n/a	n/a	n/a	n/a	
mitoxantrone	synthetic	2006	-	WO 2007027560	US2006033423	PI 0616126-0	n/a	n/a	n/a	
mitoxantrone	synthetic	2007	-	WO 2008024484	US2007018769	n/a	n/a	n/a	n/a	
natalizumab	biological	1995	US 2010081793	WO9519790	US1995001219	n/a	n/a	n/a	n/a	
natalizumab	biological	1996	US 2010081793	WO9718838	US1996018807	n/a	n/a	n/a	n/a	
natalizumab	biological	2000	-	00/64474	US2000010781	PI0010669	Rejected	2	n/a	
natalizumab	biological	2003	-	2003/072040	US2003005421	PI0307975	Pending	2	n/a	
natalizumab	biological	2004	CA 2515444	WO2004071439	PCT/US2004/003873	n/a	n/a	n/a	n/a	
natalizumab	biological	2005	-	2005/076843	US2005002860	PI0507451	Dismissed	n/a	n/a	
natalizumab	biological	2005	-	2005/113003	US2005012984	PI0508762	Dismissed	n/a	n/a	
natalizumab	biological	2005	-	WO 2006023629	US2005029368	n/a	n/a	n/a	n/a	
natalizumab	biological	2005	-	WO 2006023649	US2005029403	n/a	n/a	n/a	n/a	
natalizumab	biological	2005	-	WO 2006023651	US2005029407	n/a	n/a	n/a	n/a	
natalizumab	biological	2005	-	WO 2006036371	US2005029569	n/a	n/a	n/a	n/a	
natalizumab	biological	2005	-	WO 2006060787	US2005043980	n/a	n/a	n/a	n/a	
natalizumab	biological	2006	-	WO2006107962	US2006012493	n/a	n/a	n/a	n/a	
natalizumab	biological	2007	US2007207141; US2017022276; US 2017247457	WO2007100770	US2007004943	n/a	n/a	n/a	n/a	
natalizumab	biological	2007	-	WO2007103112	US2007005265	PI0708392	Dismissed	n/a	n/a	
natalizumab	biological	2008	US2008311119; US 2013017193	WO2008157356	US2008066928	PI 0814252-1	Pending	2	n/a	
natalizumab	biological	2010	-	WO 2010121141	US2010031407	PI 1011389-4	Pending	2	n/a	
nilotinib	synthetic	2003	US7169791; CA2491632	WO2004005281	PCT/EP2003/007198	PI0312464	Pending	3	3	
nilotinib	synthetic	2003	US7169791	WO2004005281	PCT/EP2003/007198	PI0318802-7	Pending	3	3	
nilotinib	synthetic	2003	US7169791	WO2004005281	PCT/EP2003/007198	BR 12 2017 002563 5	Pending	2	n/a	
nilotinib	synthetic	2004	-	2005/049032	EP2004013045	PI0416680	Pending	2	n/a	
nilotinib	synthetic	2006	-	2006/079539	EP2006000686	PI0606872	Dismissed	n/a	n/a	

Supplemental File: Medicines under exclusivity situation funded by the Ministry of Health: analysis of the patent situation and public procurement. Gabriela Costa Chaves, et al. Fiocruz.

nilotinib	synthetic	2006	-	2006/119154	US2006016541	PI0609296	Pending	2	n/a	
nilotinib	synthetic	2006	-	2006/117185	EP2006004084	PI0611092	Pending	2	n/a	
nilotinib	synthetic	2006	-	2006/135641	US2006022155	PI0611663	Pending	1	2	
nilotinib	synthetic	2006	-	2006/135640	US2006022154	PI0611683	Pending	2	n/a	
nilotinib	synthetic	2006	-	2006/135619	US2006022026	PI0611924	Pending	2	n/a	
nilotinib	synthetic	2006	US8163904; US8389537; CA2615669	WO2007015871	PCT/US2006/027878	PI0613605	Pending	2	n/a	
nilotinib	synthetic	2006	US8415363; CA2614334	WO2007015870	PCT/US2006/027875	PI0613615	Pending	2	n/a	
nilotinib	synthetic	2007	US8293756; US8501760	WO2008037716	PCT/EP2007/060165	PI0719438	Pending	2	n/a	
nilotinib	synthetic	2010	US9061029	WO2011062927	PCT/US2010/056926	BR 11 2012 011693	Pending	2	n/a	
nilotinib	synthetic	2012	-	2012/174082	US2012042205	BR 11 2013 032122 9	Pending	2	n/a	
nilotinib	synthetic	2012	-	2013/074432	US2012064610	BR 11 2014 011518 4	Pending	2	n/a	
pazopanib	synthetic	2001	US7105530; US7262203; US8114885; CA2432000	WO02059110	PCT/US2001/049367	PI0116452	Rejected	3	1	
pazopanib	synthetic	2011	-	2011/140343	US2011035363	BR 11 2012 028291 3	Pending	2	n/a	
penicillamine	synthetic	1943	NL 54729	n/a	n/a	n/a	n/a	n/a	n/a	
penicillamine	synthetic	1947	GB584918	n/a	n/a	n/a	n/a	n/a	n/a	
penicillamine	synthetic	1960	GB854339	n/a	n/a	n/a	n/a	n/a	n/a	
penicillamine	synthetic	2006	-	WO 2007067331	US2006044828	n/a	n/a	n/a	n/a	
penicillamine	synthetic	2008	-	WO 2008089916	EP2008000346	n/a	n/a	n/a	n/a	
penicillamine	synthetic	2008	-	WO 2008136000	IL2008000628	n/a	n/a	n/a	n/a	
penicillamine	synthetic	2008	-	WO 2009078782	SE2008000700	n/a	n/a	n/a	n/a	
penicillamine	synthetic	2015	JP 2014235058	WO 2016094415	US2015064519	n/a	n/a	n/a	n/a	
pertuzumab	biological	2000	CA2376596	WO0100245	PCT/US2000/017366	PI0012198	Granted	3	1	
pertuzumab	biological	2000	CA2376596	WO0100245	PCT/US2000/017366	BR 12 2014 028365 2	Pending	2	n/a	
pertuzumab	biological	2000	CA2490758	WO2004008099	PCT/US2000/017366	PI0312534	Pending	2	n/a	
pertuzumab	biological	2001	CA2376596	WO0100244	PCT/EP2001/004643	PI0012196	n/a	n/a	n/a	
pertuzumab	biological	2005	-	WO_2006_007398	PCT/US2005/021286	PI0511377-6	Pending	2	n/a	
pertuzumab	biological	2005	CA2574821	WO2006033700	PCT/US2005/025084	PI0513681	Pending	2	n/a	
pertuzumab	biological	2005	CA2579861	WO2006044908	PCT/US2005/037471	PI0516299	Pending	3	2	
pertuzumab	biological	2005	-	WO_2006_063042	PCT/US2005/044247	PI 0518086-4	Dismissed	2	n/a	
pertuzumab	biological	2005	-	WO_2006_078307	PCT/US2005/021287	PI 0518104-6	Pending	2	n/a	
pertuzumab	biological	2005	-	WO/2006/063707	EP2005012992	PI 0519023-1	n/a	n/a	n/a	
pertuzumab	biological	2006	CA2596133	WO2006091693	PCT/US2006/006334	PI0606542	Pending	2	n/a	
pertuzumab	biological	2006	-	WO_2006_086730	PCT/US2006/004926	PI0606557-0	Dismissed	n/a	n/a	
pertuzumab	biological	2006	-	WO_2007_013950	PCT/US2006/028120	n/a	n/a	n/a	n/a	
pertuzumab	biological	2006	-	WO_2007_097812	PCT/US2006/060460	n/a	n/a	n/a	n/a	
pertuzumab	biological	2007	-	WO_2007_145862	PCT/US2007/013028	n/a	n/a	n/a	n/a	

Supplemental File: Medicines under exclusivity situation funded by the Ministry of Health: analysis of the patent situation and public procurement. Gabriela Costa Chaves, et al. Fiocruz.

pertuzumab	biological	2008	-	WO_2009_154651	PCT/US2008/085416	n/a	n/a	n/a	n/a	
pertuzumab	biological	2008	-	n/a	n/a	PI0812682-8	Pending	2	n/a	
pertuzumab	biological	2009	CA2711798	WO2009099829	PCT/US2009/032220	PI0905733	Pending	2	n/a	
pertuzumab	biological	2009	-	WO_2009_111707	PCT/US2009/036344	n/a	n/a	n/a	n/a	
pertuzumab	biological	2009	-	WO_2010_010051	PCT/EP2009/059269	n/a	n/a	n/a	n/a	
pertuzumab	biological	2010	-	WO_2011_069104	PCT/US2010/058958	BR 11 2012 012983	Pending	3	2	
pertuzumab	biological	2011	-	WO_2011_146568	PCT/US2011/036927	n/a	n/a	n/a	n/a	
pertuzumab	biological	2012	-	WO_2013_055874	PCT/US2012/059683	BR 11 2014 007521 2	Pending	2	n/a	
pertuzumab	biological	2012	-	WO_2012_155019	PCT/US2012/037455	n/a	n/a	n/a	n/a	
pertuzumab	biological	2012	-	WO_2012_163519	PCT/EP2012/002278	n/a	n/a	n/a	n/a	
pertuzumab	biological	2016	-	WO_2016_135239	PCT/EP2016/053972	n/a	n/a	n/a	n/a	
pertuzumab	biological	2012	-	WO_2013_083810	PCT/EP2012/074857	n/a	n/a	n/a	n/a	
pertuzumab	biological	2012	-	WO_2013_096812	PCT/US2012/071331	n/a	n/a	n/a	n/a	
pertuzumab	biological	2013	-	WO_2013_135588	PCT/EP2013/054768	BR 11 2014 022932 5	Pending	3	3	
pertuzumab	biological	2013	-	WO_2014_001325	PCT/EP2013/063259	BR 11 2014 028368 0	Pending	3	2	
pertuzumab	biological	2013	-	WO_2014_001324	PCT/EP2013/063258	BR 11 2014 032193 0	Pending	3	2	
pertuzumab	biological	2013	-	WO_2014_041072	PCT/EP2013/068910	BR 11 2015 003938 3	Pending	3	2	
pertuzumab	biological	2013	-	WO_2014_070957	PCT/US2013/067621	BR 11 2015 009752 9	Pending	2	n/a	
pertuzumab	biological	2013	-	WO_2014_083178	PCT/EP2013/075162	BR 11 2015 012644 8	Pending	2	n/a	
pertuzumab	biological	2013	-	WO_2014_014796_A1	PCT/US2013/050436	n/a	n/a	n/a	n/a	
pertuzumab	biological	2013	-	WO_2014_082179_A1	PCT/CA2013/050914	n/a	n/a	n/a	n/a	
pertuzumab	biological	2014	-	WO_2015_073743_A2	PCT/US2014/065571	n/a	n/a	n/a	n/a	
pertuzumab	biological	2014	-	WO_2014_150973_A1	PCT/US2014/024688	n/a	n/a	n/a	n/a	
pertuzumab	biological	2014	-	WO_2014_182970_A1	PCT/US2014/037401	n/a	n/a	n/a	n/a	
pertuzumab	biological	2014	-	WO_2014_172371	PCT/US2014/034200	BR 11 2015 024926 4	Pending	2	n/a	
pertuzumab	biological	2014	-	WO_2015_091738	PCT/EP2014/078375	BR 11 2016 010706 3	Pending	2	n/a	
pertuzumab	biological	2015	-	WO_2015_164665	PCT/US2015/027388	BR 11 2016 024789 2	Pending	2	n/a	
pertuzumab	biological	2015	-	WO_2016_040723	PCT/US2015/049549	BR 11 2017 004631 8	Pending	2	n/a	
pertuzumab	biological	2015	-	WO_2016_044396	PCT/US2015/050382	BR 11 2017 004953 8	Pending	2	n/a	
pertuzumab	biological	2015	-	WO_2016_096788	PCT/EP2015/079693	BR 11 2017 011170 5	Pending	2	n/a	
pertuzumab	biological	2015	-	WO_2015_105926_A1	PCT/US2015/010547	n/a	n/a	n/a	n/a	
pertuzumab	biological	2015	-	WO_2015_113476_A1	PCT/CN2015/071289	n/a	n/a	n/a	n/a	
pertuzumab	biological	2015	-	WO_2015_197919_A1	PCT/FI2015/050466	n/a	n/a	n/a	n/a	
pertuzumab	biological	2015	-	WO_2016_082044_A1	PCT/CA2015/051238	n/a	n/a	n/a	n/a	
pertuzumab	biological	2015	-	WO_2016_082677_A1	PCT/CN2015/094235	n/a	n/a	n/a	n/a	
pertuzumab	biological	2015	-	WO_2016_106158_A1	PCT/US2015/066952	n/a	n/a	n/a	n/a	
pertuzumab	biological	2015	-	WO_2015_127158_A1	PCT/US2015/016737	n/a	n/a	n/a	n/a	
pertuzumab	biological	2016	-	WO_2016_127790	PCT/CN2016/072129	BR 11 2017 016503 1	Pending	2	n/a	
raltegravir	synthetic	2000	-	2000/78996	US2000017178	PI0011939-3	n/a	n/a	n/a	
raltegravir	synthetic	2002	US7169780; US7217713; US7435734; CA2463976	WO03035077		PI0213522	Pending	2	n/a	
raltegravir	synthetic	2005	-	2006/060731	US2005043782	PI0518741-9	Dismissed	2	n/a	

Supplemental File: Medicines under exclusivity situation funded by the Ministry of Health: analysis of the patent situation and public procurement. Gabriela Costa Chaves, et al. Fiocruz.

raltegravir	synthetic	2005	US7754731; CA2588398	WO2006060712		PI0518760	Pending	2	n/a	
raltegravir	synthetic	2005	US7754731; CA2588398	WO2006060730	PCT/US2005/043781	n/a	n/a	n/a	n/a	
raltegravir	synthetic	2005	CA2588445	WO2006060711		PI0518781	Dismissed	2	n/a	
raltegravir	synthetic	2010	US9649311; CA2777937	WO2011053504		BR112012009857	Pending	2	n/a	
rituximab	biological	1992	-	n/a	n/a	PP1100622-6	Expired	2	n/a	
rituximab	biological	1998	CA2635352	WO9856418	PCT/US1998/012209	n/a	n/a	n/a	n/a	
rituximab	biological	1999	CA2340091	WO0009160	PCT/US1999/018120	PI9913645	Rejected	2	n/a	
rituximab	biological	1999	CA2340091	WO0009160	PCT/US1999/018120	PI9917757-9	Rejected	2	n/a	
rituximab	biological	1999	CA2350064	WO0027433	PCT/US1999/024012	PI9915149	Rejected	2	n/a	
rituximab	biological	1999	CA2350058	WO0027428	PCT/US1999/026308	PI9915164	Rejected	2	n/a	
rituximab	biological	1999	CA2350058	WO0027428	PCT/US1999/026308	PI9917845-1	Dismissed	n/a	n/a	
rituximab	biological	2000	CA2378574	WO0110460	PCT/US2000/019563	n/a	n/a	n/a	n/a	
rituximab	biological	2000	CA2372603; CA2904259	WO0067796	PCT/US2000/040018	PI0011197	Rejected	2	n/a	
rituximab	biological	2000	-	2001/003734	US2000018776	PI0013201	Rejected	2	n/a	
rituximab	biological	2001	-	2001/74388	US2001010382	PI0109705	Dismissed	n/a	n/a	
rituximab	biological	2001	-	2001/80884	US2001013264	PI0110364	Dismissed	n/a	n/a	
rituximab	biological	2002	-	WO_2002_060955	PCT/US2002/002373	PI0206985	Dismissed	3	1	
rituximab	biological	2002	-	WO_2002_096948	PCT/US2002/002374	n/a	n/a	n/a	n/a	
rituximab	biological	2003	-	2004/060920	US2003041691	PI0317896	Dismissed	n/a	n/a	
rituximab	biological	2004	-	2004/091657	US2004010509	PI0409534	Pending	2	n/a	
rituximab	biological	2004	-	WO_2004_099249	PCT/US2004/009298	PI0410031-0	Pending	3	1	
rituximab	biological	2004	-	2005/017529	US2004020069	PI0412217	Dismissed	n/a	n/a	
rituximab	biological	2004	-	2005/023302	US2004027164	PI0412629	Dismissed	n/a	n/a	
rituximab	biological	2004	-	2005/060999	US2004040949	PI0417105	Dismissed	n/a	n/a	
rituximab	biological	2004	-	2005/061542	US2004040947	PI0417108	Dismissed	n/a	n/a	
rituximab	biological	2004	-	WO_2005_000898	PCT/US2004/020944	n/a	n/a	n/a	n/a	
rituximab	biological	2005	-	2005/115453	US2005012961	PI0509412	Dismissed	n/a	n/a	
rituximab	biological	2005	-	2005/117972	US2005015337	PI0510224	Dismissed	n/a	n/a	
rituximab	biological	2005	-	WO_2006_019447	PCT/US2005/015935	PI0510674-5	Pending	1	1	
rituximab	biological	2005	-	2005/120437	US2005019550	PI0510885	Dismissed	n/a	n/a	
rituximab	biological	2005	-	2005/117978	US2005019641	PI0510915	Pending	2	n/a	
rituximab	biological	2005	-	WO_2006_031370	PCT/US2005/029511	PI0515230-5	Dismissed	n/a	n/a	
rituximab	biological	2005	-	2006/041680	US2005034647	PI0516297	Dismissed	n/a	n/a	
rituximab	biological	2005	-	WO_2006_047350	PCT/US2005/038064	n/a	n/a	n/a	n/a	
rituximab	biological	2005	-	WO_2006_085967	PCT/US2005/023328	n/a	n/a	n/a	n/a	
rituximab	biological	2006	-	2006/076651	US2006001361	PI0606108	Dismissed	n/a	n/a	
rituximab	biological	2006	-	2006/093923	US2006006998	PI0608109	Dismissed	n/a	n/a	
rituximab	biological	2006	-	WO_2006_126069	PCT/IB2006/001358	PI0610203-4	Dismissed	n/a	n/a	
rituximab	biological	2006	-	2006/113308	US2006013780	PI0612321	Dismissed	n/a	n/a	
rituximab	biological	2006	-	2006/125140	US2006019404	PI0612947	Dismissed	n/a	n/a	

Supplemental File: Medicines under exclusivity situation funded by the Ministry of Health: analysis of the patent situation and public procurement. Gabriela Costa Chaves, et al. Fiocruz.

rituximab	biological	2006	-	2006/127517	US2006019576	PI0613259	Dismissed	n/a	n/a	
rituximab	biological	2006	CA2783210	WO2007059188	PCT/US2006/044290	PI0618577	Pending	2	n/a	
rituximab	biological	2008	-	WO_2009_016164	PCT/EP2008/059900	PI0814471-0	Dismissed	n/a	n/a	
rituximab	biological	2010	CA2771571	WO2011029892	PCT/EP2010/063271	BR 11 2012 005017 6	Pending	2	n/a	
rituximab	biological	2011	-	WO_2012_003995	PCT/EP2011/003418	BR 11 2013 000603 0	Dismissed	n/a	n/a	
rituximab	biological	2011	-	WO_2012_041768	PCT/EP2011/066554	n/a	n/a	n/a	n/a	
rituximab	biological	2012	-	WO_2012_098119	PCT/EP2012/050645	BR 11 2013 018130 3	Pending	3	2	
rituximab	biological	2012	-	WO_2013_004806	PCT/EP2012/063207	BR 11 2013 033944 6	Pending	2	n/a	
rituximab	biological	2012	-	WO_2013_059885	PCT/AU2012/001323	BR 11 2014 009925 1	Pending	2	n/a	
rituximab	biological	2012	-	WO_2013_109279	PCT/US2012/021888	n/a	n/a	n/a	n/a	
rituximab	biological	2012	-	WO_2012_099949	PCT/US2012/021704	n/a	n/a	n/a	n/a	
rituximab	biological	2013	-	WO_2014_031646	PCT/US2013/055800	BR 11 2015 003459 4	Pending	3	1	
rituximab	biological	2013	-	WO_2013_163297	PCT/US2013/037997	n/a	n/a	n/a	n/a	
rituximab	biological	2013	-	WO_2014_079309	PCT/CN2013/086268	n/a	n/a	n/a	n/a	
rituximab	biological	2013	-	WO_2013_134138	PCT/US2013/028899	n/a	n/a	n/a	n/a	
rituximab	biological	2014	-	WO_2014_144357	PCT/US2014/028731	BR 11 2015 021921 7	Pending	3	3	
rituximab	biological	2014	-	WO_2015_053887	PCT/US2014/054079	BR 11 2016 004768 0	Pending	3	1	
rituximab	biological	2014	-	WO_2014_114771_A1	PCT/EP2014/051448	n/a	n/a	n/a	n/a	
rituximab	biological	2014	-	WO_2015_010114_A1	PCT/US2014/047336	n/a	n/a	n/a	n/a	
rituximab	biological	2015	-	WO_2015_103704	PCT/CA2015/050009	BR 11 2016 015875 0	Pending	3	2	
rituximab	biological	2015	-	WO_2015_167278	PCT/KR2015/004389	BR 11 2016 024895 3	Pending	3	2	
rituximab	biological	2015	-	WO_2015_110923	PCT/IB2015/000645	n/a	n/a	n/a	n/a	
rituximab	biological	2014	-	WO_2015_018522	PCT/EP2014/002165	n/a	n/a	n/a	n/a	
rituximab	biological	2015	-	WO_2016_022971	PCT/US2015/044304	n/a	n/a	n/a	n/a	
rituximab	biological	2015	-	WO_2016_062898	PCT/EP2015/074752	n/a	n/a	n/a	n/a	
rituximab	biological	2015	-	WO_2016_024232	PCT/IB2015/056128	n/a	n/a	n/a	n/a	
rituximab	biological	2015	-	WO_2016_024230	PCT/IB2015/056126	n/a	n/a	n/a	n/a	
rituximab	biological	2015	-	WO_2016_024227	PCT/IB2015/056122	n/a	n/a	n/a	n/a	
rituximab	biological	2015	-	WO_2016_087994	PCT/IB2015/059100	n/a	n/a	n/a	n/a	
rituximab	biological	2015	-	WO_2016_116777	PCT/IB2015/002140	n/a	n/a	n/a	n/a	
rituximab	biological	2015	-	WO_2016_073917	PCT/US2015/059574	n/a	n/a	n/a	n/a	
rituximab	biological	2016	-	WO_2016_144773	PCT/US2016/020931	n/a	n/a	n/a	n/a	
rituximab	biological	2016	-	WO_2016_151599	PCT/IN2016/050089	n/a	n/a	n/a	n/a	
simeprevir	synthetic	2005	US7671032; CA2552319	WO2005073216	SE2005000096	PI0506945	Pending	2	n/a	
simeprevir	synthetic	2005	US7671032; CA2552319	WO2005073195	SE2005000097	PI0506948	Pending	2	n/a	
simeprevir	synthetic	2006	US8148399; US8349869; US8741926; US8754106; US9040562; US9353103; US9623022; CA2616580	WO2007014926	EP2006064820	PI0614654	Pending	3	3	
simeprevir	synthetic	2008	-	2008/092955	EP2008051269	PI0806853-4	Pending	2	n/a	

Supplemental File: Medicines under exclusivity situation funded by the Ministry of Health: analysis of the patent situation and public procurement. Gabriela Costa Chaves, et al. Fiocruz.

simeprevir	synthetic	2008	CA2677170	WO2008092954	EP2008051268	PI0806945	Pending	2	n/a	
simeprevir	synthetic	2009	-	2010/031829	EP2009062096	PI0919404	Dismissed	2	n/a	
simeprevir	synthetic	2009	-	2010/072742	EP2009067715	PI0923393	Pending	3	2	
simeprevir	synthetic	2010	CA2753667	WO2010097229	EP2010001197	PI1008918	Granted	2	n/a	
sirolimus	synthetic	1982	-	n/a	n/a	PP1100594	Extinct	2	n/a	
sirolimus	synthetic	1990	US5100899; US5212155; US5308847; US5403833	n/a	n/a	n/a	n/a	n/a	n/a	
sirolimus	synthetic	1993	US5145684	WO9325190	PCT/US1993/005082	n/a	n/a	n/a	n/a	
sirolimus	synthetic	1993	-	n/a	n/a	PP1100753	Extinct	n/a	n/a	
sirolimus	synthetic	1993	-	n/a	n/a	PP1100818	Extinct	2	n/a	
sirolimus	synthetic	1993	-	n/a	n/a	PP1100825	Expired	n/a	n/a	
sirolimus	synthetic	1993	-	n/a	n/a	PI9301667	Dismissed	2	n/a	
sirolimus	synthetic	1994	-	n/a	n/a	PI9403945	Dismissed	2	n/a	
sirolimus	synthetic	1994	US5536729	n/a	n/a	PI9403946	Dismissed	2	n/a	
sirolimus	synthetic	1994	-	n/a	n/a	PI9403947	Dismissed	n/a	n/a	
sirolimus	synthetic	1994	US5536729	n/a	n/a	PI9403948	Dismissed	n/a	n/a	
sirolimus	synthetic	1994	-	n/a	n/a	PI9403949	Dismissed	n/a	n/a	
sirolimus	synthetic	1994	-	n/a	n/a	PI9404265	Dismissed	n/a	n/a	
sirolimus	synthetic	1994	-	1995/001785	EP1994002238	PI9407002	Rejected	2	n/a	
sirolimus	synthetic	1995	-	96/13273	EP1995004187	PI9509496	Rejected	2	n/a	
sirolimus	synthetic	1996	-	n/a	n/a	PI9600969	Rejected	2	n/a	
sirolimus	synthetic	1996	-	n/a	n/a	PI9605895	Dismissed	n/a	n/a	
sirolimus	synthetic	1998	CA2230748	n/a	n/a	PI9801120	Granted	2	n/a	
sirolimus	synthetic	1998	-	98/56358	US1998012142	PI9810746	Dismissed	n/a	n/a	
sirolimus	synthetic	1998	-	99/24036	GB1998003317	PI9815264	Dismissed	2	n/a	
sirolimus	synthetic	1998	US5989591	n/a	n/a	n/a	n/a	n/a	n/a	
sirolimus	synthetic	2001	-	01/97809	US2001019179	PI0111601	Dismissed	n/a	n/a	
sirolimus	synthetic	2003	-	03/057218	EP2003000153	PI0306858	Dismissed	n/a	n/a	
sirolimus	synthetic	2003	-	03/077915	US2003007334	PI0308587	Dismissed	n/a	n/a	
sirolimus	synthetic	2004	-	2005/005434	EP2004007437	PI0412404	Pending	2	n/a	
sirolimus	synthetic	2004	-	2005/070393	US2004042178	PI0418373	Dismissed	n/a	n/a	
sirolimus	synthetic	2005	-	2005/105812	US2005012268	PI0509810	Dismissed	n/a	n/a	
sirolimus	synthetic	2005	-	2005/105811	US2005012266	PI0509852	Pending	3	2	
sirolimus	synthetic	2005	-	2005/106007	US2005013971	PI0510277	Dismissed	n/a	n/a	
sirolimus	synthetic	2005	-	2006/023627	US2005029364	PI0514407	Dismissed	n/a	n/a	
sirolimus	synthetic	2005	-	2006/029726	EP2005009468	PI0515378	Dismissed	n/a	n/a	
sirolimus	synthetic	2005	-	2006/050461	US2005039836	PI0518079	Dismissed	n/a	n/a	
sirolimus	synthetic	2006	-	2007/075621	US2006048329	PI0620213-6	Dismissed	2	n/a	
sirolimus	synthetic	2007	-	2007/103348	US2007005646	PI0708562	Dismissed	n/a	n/a	
sofosbuvir	synthetic	2001	-	2001/90121	US2001016671	PI0111127-2	Pending	2	n/a	
sofosbuvir	synthetic	2003	-	2004/002999	IB2003003246	PI0312286-7	Pending	2	n/a	

Supplemental File: Medicines under exclusivity situation funded by the Ministry of Health: analysis of the patent situation and public procurement. Gabriela Costa Chaves, et al. Fiocruz.

sofosbuvir	synthetic	2004	-	2005/003147	US2004012472	PI0419342-3	Pending	2	n/a	
sofosbuvir	synthetic	2004	-	2005/003147	US2004012472	PI0419343-1	Pending	2	n/a	
sofosbuvir	synthetic	2004	-	2005/003147	US2004012472	PI0419344-0	Pending	2	n/a	
sofosbuvir	synthetic	2004	-	2005/003147	US2004012472	PI0419345-8	Pending	2	n/a	
sofosbuvir	synthetic	2004	-	2005/003147	US2004012472	PI0410846-9	Pending	3	3	
sofosbuvir	synthetic	2008	US7964580; US8334270; US8580765; US9085573; CA2682230	WO/2008/121634	PCT/US2008/058183	PI0809654	Pending	3	3	
sofosbuvir	synthetic	2008	US7964580; US8334270; US8580765; US9085573; CA2682230	WO/2008/121634	PCT/US2008/058183	PI0823519	Pending	3	1	
sofosbuvir	synthetic	2009	-	2010/075549	US2009069469	PI0922507-2	Dismissed	2	n/a	
sofosbuvir	synthetic	2010	US8618076; US8633309; US9284342; CA2794669	WO2010135569	PCT/US2010/035641	PI1012781	Pending	2	n/a	
sofosbuvir	synthetic	2010	US8618076; US8633309; US9284342; CA2794669	WO2010135569	PCT/US2010/035641	BR122013007556	Pending	3	2	
sofosbuvir	synthetic	2011	US8618076; US8633309; US9284342; CA2794669	WO2011123668	PCT/US2011/030762	BR112012024884	Pending	2	n/a	
sofosbuvir	synthetic	2011	US8618076; US8633309; US9284342; CA2794669	WO2011123645	PCT/US2011/030725	BR112012024923	Pending	2	n/a	
sofosbuvir	synthetic	2011	US8618076; US8633309; US9284342; CA2794669	WO2011123645	PCT/US2011/030725	BR122013004621	Pending	3	2	
sofosbuvir	synthetic	2011	US8618076; US8633309; US9284342; CA2794669	WO2011123672	PCT/US2011/030767	n/a	n/a	n/a	n/a	
sofosbuvir	synthetic	2012	US8889159; US9549941	WO2013040492	PCT/US2012/055621	BR112014006324	Pending	2	n/a	
sofosbuvir	synthetic	2012	US8889159; US9549941	WO2013066748	PCT/US2012/062115	BR112014010295	Pending	2	n/a	
sofosbuvir	synthetic	2012	US8889159; US9549941	WO2013082003	PCT/US2012/066605	BR112014012739	Pending	2	n/a	
sofosbuvir	synthetic	2014	-	2014/120981	US2014013953	BR 11 2014 011938 4	Pending	2	n/a	
sofosbuvir	synthetic	2014	-	2015/030853	US2014013930	BR 11 2016 003644 1	Pending	2	n/a	
sofosbuvir	synthetic	2014	-	2015/099989	US2014069123	BR 11 2016 013714 0	Pending	2	n/a	
sofosbuvir	synthetic	2014	-	2015/099989	US2014069123	BR 11 2016 013714 0	Pending	2	n/a	
sorafenib	synthetic	1998	CA2315646	WO9932436	PCT/US1998/026081	PI9814375	Dismissed	2	n/a	
sorafenib	synthetic	1998	CA2315715	WO9932463	PCT/US1998/027265	n/a	n/a	n/a	n/a	

Supplemental File: Medicines under exclusivity situation funded by the Ministry of Health: analysis of the patent situation and public procurement. Gabriela Costa Chaves, et al. Fiocruz.

sorafenib	synthetic	2000	US7351834; US7897623; US8124630; US8841330; CA2359244; CA2359510	WO0042012	PCT/US2000/000648	PI0007487	Granted	2	n/a	
sorafenib	synthetic	2000	US7351834; US7897623; US8124630; US8841330; CA2359244; CA2359510	WO0042012	PCT/US2000/000648	PI 0017535-8	Pending	3	1	
sorafenib	synthetic	2000	US7351834; US7897623; US8124630; US8841330; CA2359244; CA2359510	WO0041698	PCT/US2000/000768	n/a	n/a	n/a	n/a	
sorafenib	synthetic	2001	US7235576	n/a	n/a	n/a	n/a	n/a	n/a	
sorafenib	synthetic	2002	US7351834; US7897623; US8124630; US8841330; CA2359244; CA2359510	WO02062763	PCT/US2002/003361	n/a	n/a	n/a	n/a	
sorafenib	synthetic	2002	US7351834; US7897623; US8124630; US8841330; CA2359244; CA2359510	WO02085859	PCT/US2002/012064	n/a	n/a	n/a	n/a	
sorafenib	synthetic	2003	US8618141; CA2475703	WO03068228	PCT/US2003/004103	n/a	n/a	n/a	n/a	
sorafenib	synthetic	2004	CA2526617; CA2526636	WO2004113274	PCT/US2004/015655	n/a	n/a	n/a	n/a	
sorafenib	synthetic	2004	CA2526617; CA2526636	WO2005000284	PCT/US2004/015653	n/a	n/a	n/a	n/a	
sorafenib	synthetic	2005	-	2006/034796	EP2005010118	PI0515944	Pending	2	n/a	
sorafenib	synthetic	2005	US8877933; CA2581843	WO2006034797	PCT/EP2005/010119	PI0515946	Pending	2	n/a	
sorafenib	synthetic	2006	US9737488; CA2601955	WO2006094626	PCT/EP2006/001574	PI0608840	Pending	2	n/a	
sorafenib	synthetic	2006	-	2007/054215	EP2006010405	PI0618524	Dismissed	n/a	n/a	
sorafenib	synthetic	2006	-	2007/059094	US2006044117	PI0618597-5	Dismissed	2	n/a	
sorafenib	synthetic	2013	-	2013/178581	EP2013060854	BR 11 2014 029338 4	Pending	2	n/a	
sunitinib	synthetic	2000	US7211600; CA2395461	WO0145689	PCT/US2000/035009	n/a	n/a	n/a	n/a	
sunitinib	synthetic	2001	US6573293; US7125905; CA2399358	WO0160814	PCT/US2001/004813	PI0108394	Pending	3	1	
sunitinib	synthetic	2001	US6573293	WO0160814	PCT/US2001/004813	PI 0117360-0	Pending	2	n/a	
sunitinib	synthetic	2001	US6573293	WO0160814	PCT/US2001/004813	PI 0117361-8	Dismissed	2	n/a	
sunitinib	synthetic	2002	CA2455050	WO03016305	PCT/US2002/025649	PI0211612	Pending	2	n/a	

Supplemental File: Medicines under exclusivity situation funded by the Ministry of Health: analysis of the patent situation and public procurement. Gabriela Costa Chaves, et al. Fiocruz.

sunitinib	synthetic	2002	-	2003/035009	US2002034525	PI0213960	Dismissed	n/a	n/a	
sunitinib	synthetic	2003	-	2003/070725	US2003004520	PI0307721	Dismissed	n/a	n/a	
sunitinib	synthetic	2003	CA2498415	WO2004024127	PCT/IB2003/005293	PI0314182	Dismissed	3	1	
sunitinib	synthetic	2004	-	2004/073592	EP2004050058	PI0407596	Dismissed	n/a	n/a	
sunitinib	synthetic	2006	-	2006/101692	US2006007651	PI0607579	Dismissed	n/a	n/a	
sunitinib	synthetic	2006	-	2006/120557	IB2006001251	PI0609957-2	Dismissed	2	n/a	
sunitinib	synthetic	2008	-	2008/094969	US2008052406	PI0806414	Dismissed	n/a	n/a	
temsirolimus	synthetic	1995	US5362718; USRE44768	WO9528406	PCT/US1995/004603	PI9507323	Granted	3	3	
temsirolimus	synthetic	2001	CA2429020	WO0240000	PCT/US2001/047324	PI0115323	Rejected	2	n/a	
temsirolimus	synthetic	2003	US8026276; US8299116; US8455539; US8722700; CA2493878	WO2004011000	PCT/US2003/023276	PI0313024	Pending	2	n/a	
temsirolimus	synthetic	2003	US8026276	WO2004011000	PCT/US2003/023276	BR 12 2014 017871 9	Pending	2	n/a	
temsirolimus	synthetic	2006	-	2007/056118	US2006042915	PI 0618042	Pending	2	n/a	
temsirolimus	synthetic	2008	US8791097	WO2008124125	PCT/US2008/004501	PI0809322	Pending	2	n/a	
tipranavir	synthetic	1994	US5852195; US6169181	WO9530670		PI9507615	Pending	2	n/a	
tipranavir	synthetic	1998	US6231887; CA2294033	WO9906024		PI9810729	Granted	2	n/a	
tipranavir	synthetic	1998	US6231887; CA2294033	WO9906043		PI9810866	Extinct	2	n/a	
tipranavir	synthetic	1998	US6231887; CA2294033	WO9906044		PI9811058	Rejected	2	n/a	
tipranavir	synthetic	1999	US6147095; CA2346131	WO0025784		PI9914940	Rejected	2	n/a	
tipranavir	synthetic	2001	-	2002/036110	US2001048683	PI0114969-5	Dismissed	3	1	
tipranavir	synthetic	2002	-	2003/066564	JP2002011348	PI0215593-1	Dismissed	2	n/a	
tipranavir	synthetic	2002	-	2003/030871	US2002032303	PI0213155-2	Dismissed	2	n/a	
tocilizumab	biological	1989	CA 1341152	n/a	n/a	n/a	n/a	n/a	n/a	
tocilizumab	biological	1992	-	n/a	n/a	PP1101027	Expired	3	1	
tocilizumab	biological	2002	CA 2443294	WO2002080969	JP2002003312	PI0208636	Pending	2	n/a	
tocilizumab	biological	2003	CA 2474943	WO2003068260	JP2003001563	PI0307702	Pending	2	n/a	
tocilizumab	biological	2003	CA 2474943	WO2003068259	JP2003001562	n/a	n/a	n/a	n/a	
tocilizumab	biological	2004	-	WO2004096273	JP2004006211	PI0409910	Pending	2	n/a	
tocilizumab	biological	2004	-	WO2005051293		PI0416812	Dismissed	2	n/a	
tocilizumab	biological	2004	CA2549467	WO2005061000	JP2004019463	PI0417072	Pending	2	n/a	
tocilizumab	biological	2005	-	WO2005089802	JP2005006202	PI0509127	Dismissed	n/a	n/a	
tocilizumab	biological	2008	CA 2708627	WO2009084659	JP2008073798	PI0818903	Pending	2	n/a	
tolcapone	synthetic	1986	US5236952; US5476875	n/a	n/a	n/a	n/a	n/a	n/a	

Supplemental File: Medicines under exclusivity situation funded by the Ministry of Health: analysis of the patent situation and public procurement. Gabriela Costa Chaves, et al. Fiocruz.

tolcapone	synthetic	1987	EP0237929; AU6976487	n/a	n/a	n/a	n/a	n/a	n/a	
tolcapone	synthetic	1988	EP 855379	n/a	n/a	PI9800426	Granted	3	2	
trastuzumab	biological	1989	CA1341082	WO8906692	PCT/US1989/000051	n/a	n/a	n/a	n/a	
trastuzumab	biological	1992	-	WO/1992/020789	PCT/DE1992/000371	n/a	n/a	n/a	n/a	
trastuzumab	biological	1993	-	n/a	n/a	PP1101137-8	Extinct	3	3	
trastuzumab	biological	1996	-	97/04801	US1996012251	PI9609743	Rejected	2	n/a	
trastuzumab	biological	1998	CA2311409	WO9931140	PCT/US1998/026266	PI9815363	Rejected	2	n/a	
trastuzumab	biological	1999	-	99/57134	S1999009637	PI9910332	Granted	2	n/a	
trastuzumab-emtansine	biological	2000	CA2376596; CA2370466	WO0100244	PCT/US2000/017229	PI0012196	Pending	2	n/a	
trastuzumab	biological	2000	CA2376596; CA2370466	WO0100245	PCT/US2000/017366	PI0012198	n/a	n/a	n/a	
trastuzumab	biological	2000	-	2001/015730	S2000023391	PI0013814	Rejected	2	n/a	
trastuzumab-emtansine	biological	2000	CA2376596; CA2370466	WO0100244	PCT/US2000/017229	PI0017590-0	Pending	3	1	
trastuzumab-emtansine	biological	2000	CA2376596; CA2370466	WO0100244	PCT/US2000/017229	BR 12 2012 024241 1	Rejected	2	n/a	
trastuzumab	biological	2000	CA2376596; CA2370466	WO0100245	PCT/US2000/017366	BR 12 2014 028365 2	Pending	2	n/a	
trastuzumab	biological	2001	CA2407556	WO0189566	PCT/US2001/016193	PI0111355	Pending	2	n/a	
trastuzumab	biological	2001	CA2407556	WO0189566	PCT/US2001/016193	BR 12 2012 019826 9	Rejected	2	n/a	
trastuzumab-emtansine	biological	2003	-	2004/043344	US2003032737	PI0316101	Pending	2	n/a	
trastuzumab	biological	2003	-	2004/060920	US2003041691	PI0317896	Dismissed	n/a	n/a	
trastuzumab	biological	2004	-	2004/110498	US2004015376	PI0410260-6	Pending	2	n/a	
trastuzumab	biological	2004	-	2005/009369	US2004023340	PI0412879	Pending	3	1	
trastuzumab-emtansine	biological	2004	-	2005/037992	US2004030917	PI0415448-7	Pending	3	3	
trastuzumab	biological	2005	-	2005/117986	US2005018829	PI0510883	Pending	2	n/a	
trastuzumab	biological	2005	-	2006/062779	US2005043250	PI0515745	Pending	2	n/a	
trastuzumab	biological	2005	-	2006/034488	US2005034353	PI0516284	Pending	3	3	
trastuzumab	biological	2005	-	WO/2006/063707	EP2005012992	PI 0519023-1	n/a	n/a	n/a	
trastuzumab	biological	2006	CA2540547	n/a	n/a	PI0601736	Pending	2	n/a	
trastuzumab	biological	2006	CA2596133	WO2006091693	PCT/US2006/006334	PI0606542	n/a	n/a	n/a	
trastuzumab	biological	2006	-	2006/086730	US2006004926	PI0606557	Dismissed	n/a	n/a	
trastuzumab	biological	2007	-	WO_2007_127936	PCT/US2007/067663	n/a	n/a	n/a	n/a	
trastuzumab	biological	2008	-	WO_2009_062083	PCT/US2008/082867	n/a	n/a	n/a	n/a	
trastuzumab	biological	2008	-	WO_2009_062081	PCT/US2008/082864	n/a	n/a	n/a	n/a	
trastuzumab	biological	2008	-	2008/145697	EP2008056620	PI 0812280-6	Dismissed	2	n/a	
trastuzumab	biological	2008	-	n/a	n/a	PI 0812682-8	Pending	2	n/a	
trastuzumab	biological	2009	-	WO_2009_111183	PCT/US2009/034631	n/a	n/a	n/a	n/a	
trastuzumab	biological	2010	-	WO_2011_061629	PCT/IB2010/003154	BR 11 2012 011980 0	Pending	3	2	
trastuzumab	biological	2010	-	WO_2011_075606	PCT/US2010/060891	n/a	n/a	n/a	n/a	
trastuzumab	biological	2010	-	WO_2011_028952	PCT/US2010/047741	n/a	n/a	n/a	n/a	
trastuzumab	biological	2010	-	WO_2011_003557	PCT/EP2010/004051	n/a	n/a	n/a	n/a	
trastuzumab	biological	2010	-	WO_2011_003780	PCT/EP2010/059243	n/a	n/a	n/a	n/a	

Supplemental File: Medicines under exclusivity situation funded by the Ministry of Health: analysis of the patent situation and public procurement. Gabriela Costa Chaves, et al. Fiocruz.

vemurafenib	synthetic	2006	US7863288; US8143271; US8470818; CA2613015	WO2007002433	PCT/US2006/024524	n/a	n/a	n/a	n/a	
vemurafenib	synthetic	2010	US9447089; CA2738573	WO2010114928	PCT/US2010/029489	PI1008709	Pending	2	n/a	
vemurafenib	synthetic	2010	US9447089; CA2738573	WO2011057974	PCT/EP2010/066965	BR112012009609	Dismissed	2	n/a	
vemurafenib	synthetic	2010	US8741920	WO2011015522	PCT/EP2010/061079	BR112012002251	Pending	3	3	
vemurafenib	synthetic	2013	-	2013/139724	EP2013055522	BR 11 2014 018910 2	Pending	2	n/a	